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1. Introduction 
 
1.1. Colorectal Cancer 
 
With around 14.1 million new incidences and 8.2 million deaths worldwide 
cancer represents a major cause of death throughout the world.  
The ongoing growth and aging of the population will increase this liability in 
both more and less developed countries. Especially lifestyle behaviors like 
smoking, poor diet, physical inactivity, and reproductive changes – all factors 
known to increase the risk of cancer - have further raised this burden mainly 
in less economically developed countries (Botteri et al., 2008; Giovannucci, 
2002; Karimi et al., 2014). 
Among cancer, colorectal cancer (CRC) serves as a crucial reason of 
morbidity and mortality worldwide representing over 9% of all cancer cases 
resulting in 700 thousand deaths in the year 2012. This depicts CRC as the 
third most common cancer worldwide and the fourth most common cause of 
cancer related death (Jemal et al., 2009; Torre et al., 2015; World Cancer 
Research Fund, 2007). 
CRC develops in a multistep process, that is characterized by an 
accumulation of epigenetic and genetic changes leading to the inactivation of 
tumor suppressive mechanisms and the upregulation of oncogenic pathways, 
transforming normal glandular epithelium into invasively growing 
adenocarcinomas. This highly dynamic process is referred to as 
tumorigenesis. Fearon and Vogelstein first defined the stages of this process 
in the classic adenoma-carcinoma sequence model where they suggested 
that only a limited number of genetic alterations drive the formation of CRC 
(Fearon and Vogelstein, 1990). 
By now, studies have revealed mutations in about 67 genes in a colon cancer 
genome, of those, a subgroup of twelve genes were identified to be 
predominantly involved in cancer formation. Like other typical solid tumors, 
CRC requires two to eight of these mutations to develop over time (Sjöblom et 
al., 2006; Vogelstein et al., 2013). This accumulation of mutations enables 
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normal tissue to acquire several specific capacities that have been designated 
as the hallmarks of cancer (Figure 1) (Hanahan and Weinberg, 2000, 2011).  
 
 
Figure 1: The hallmarks of cancer. The six capacities that enable invasive tumor growth 
and metastatic propagation. Figure from (Hanahan and Weinberg, 2011). 
 
The relevance of genetic aberrations in tumorigenesis can be observed in 
small single crypt adenomas; the earliest lesions of the adenoma-carcinoma 
sequence. These small adenomas typically harbor mutations in APC or β-
catenin, resulting in the activation of the WNT pathway (Vazquez et al., 2008; 
Vogelstein et al., 1988). These mutations provide selective growth advantage 
to the altered intestinal epithelial cells over surrounding cells – therefor named 
“driver mutations” whereas a “passenger mutations” does not confer selective 
growth advantage to cells in which they occur (Vogelstein et al., 2013).  
Consecutive alterations in genes like KRAS or TP53 may arise, leading to 
aberrant activation of MAPK signaling and therefore promote the clonal 
progression to cancer (Nosho et al., 2008; Samowitz et al., 2005; Vazquez et 
al., 2008; Vogelstein et al., 2013). Furthermore, this progression can also 
include mutations in genes like SMAD2, SMAD4, RUNX3, and TSP1, leading 
to a deregulation of crucial signaling pathways including the transforming 
growth factor - β (TGFB1) pathway (Figure 2) (Lao & Grady, 2011; Grady & 
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Markowitz 2008; Macías-Silva et al. 1996; Takaku et al. 1998; Wood et al. 
2007). ) 
 
Figure 2: Transformation process from normal colon epithelium to an invasive 
colorectal carcinoma. Upper panels: H&E staining of normal colon epithelium (left), 
adenoma (middle) and carcinoma (right). Lower panels: Deregulation of crucial signaling 
pathways accompanying the adenoma–carcinoma sequence. Figure adapted from (Fearon 
and Vogelstein, 1990). 
 
In general it is considered that despite a large number of different genomic or 
epigenomic instabilities that occur  in CRC, the selective pressure emerging in 
the clonal evolution is largely the same, resulting in genes that are more 
frequently altered in CRC compared to other cancer types (Fearon, 2011).  
For instance, alterations affecting the WNT/β-catenin pathway occur in about 
60% of all colorectal cancer cases, whereas KRAS or BRAF are altered in 
approximately 55-60%, and 30% carry alterations in the TGFB1 signaling 
pathway (Grady et al., 1998; Jass et al., 2002; Samowitz et al., 2005). 
However, CRCs are characterized by substantial genotypic and phenotypic 
heterogeneity and these traits confer a unique peculiarity to each tumor. Each 
CRC case thus must be considered as an individual disease with specific 
characteristics (The Cancer Genome Network Atlas, 2012). Therefore, the 
discovery of new prognostic and predictive molecular biomarkers is required 
for a better characterization of CRC and the determination of the most 
appropriate therapy.  
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1.2. Tumor heterogeneity and cancer stem cells 
 
The idea of tumor heterogeneity has been established over the last few 
decades, suggesting that cells that make up a tumor display substantial 
differences in properties like morphology, cell surface markers and genetic 
alterations. Further complexity to this heterogeneity is added by different 
extrinsic stimuli that can affect tumor development and progression including 
immune cell interactions (Cabrera, Hollingsworth, & Hurt, 2015; Campbell et 
al., 2010; Shah et al., 2009). 
Virchow and Cohnheim were the first to postulate the presence of cancer 
stem cells (CSCs) within such tumor cell heterogeneity (Huntly and Gilliland, 
2005). Later this existence was proven by Bonnet and Dick, isolating cells 
from acute myeloid leukemia (AML) that were capable to induce tumor growth 
in immune-compromised recipients (Bonnet and Dick, 1997). Furthermore it is 
well established that heterogeneity within a tumor (intratumor heterogeneity) 
evolves over time as CSCs grow and differentiate asymmetrically (Bao et al., 
2013; Lathia et al., 2011). By now, the existence of CSCs is quite well 
accepted but their role in various tumors and how they contribute to tumor 
formation and tumor cell heterogeneity remain the subject of debate and 
investigation. Still, studies depicting cellular heterogeneity together with the 
observation that tumors contain both highly tumorigenic as well as non-
tumorigenic cells suggested that cancers have an intrinsic hierarchical 
organization (Cabrera et al., 2015). 
Hence, two distinct models, known as the stochastic or clonal evolution (CE) 
model and the hierarchy or CSC model, may explain the progression and 
heterogeneity of tumors (Figure 3) (Gerdes et al. 2014; Michor & Polyak 
2010). 
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Figure 3: Models of tumor heterogeneity. Schematic illustration of the two models how 
tumor heterogeneity may arise. Figure from (Dick, 2009) 
 
According to the stochastic model, all malignant cells in principle are 
biologically equal (Dick, 2009). However, since tumor cells are genetically 
unstable and their behavior is additionally influenced by intrinsic and extrinsic 
cues, alterations may accumulate over time and may by chance increase 
characteristics such as invasiveness, tumor aggressiveness and treatment 
resistance. Natural selection then drives tumor progression and only few 
tumor cells may dominate outgrowth within a tumor. Hence according to this 
model, tumor-initiating cells may not be enriched by sorting cells based on 
phenotypic characteristics (Gerdes et al., 2014; Michor and Polyak, 2010).  
In contrast, the CSC model postulates that tumors are composed of distinct 
types of cells, each with their own capabilities and phenotypes. Only a specific 
type of cells, the CSCs, have self-renewing potential and therefore are 
capable to initiate tumor growth. Moreover, CSCs give rise to non-tumorigenic 
progeny that may make up most of the tumor mass. Unlike the CE model, the 
CSC model thus concludes that based on intrinsic characteristics, tumor-
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initiating cells can be identified and separated from the non-tumorigenic 
population (Meacham & Morrison 2013). 
As these two models are quite mutually exclusive, an alternative model of 
reversible cellular plasticity has been proposed, integrating characteristics of 
both models. In the so called plasticity model, cancer cells are capable to 
convert between stem cell and differentiated tumor cell states (Plaks et al., 
2015). These competing concepts demonstrate that our understanding of 
cellular heterogeneity in tumors still is incomplete and requires further study.     
 
 
1.3. Intestinal stem cells and colon cancer stem cells 
 
The healthy human intestine is composed 
of millions of crypts, containing 
differentiated cell lineages that reside in 
distinct functional compartments. Besides 
stem cells, these include enterocytes, 
goblet cells, tuft cells and enteroendocrine 
cells. Stem cells, located in the niche or at 
the base of the crypt, give rise to more 
differentiated cells of a transit-amplifying 
cell lineage. Differentiated colon epithelial 
cells are then subjected to a massive 
cellular turnover, being replaced 
approximately every five days. During this 
turnover, terminally differentiated cells 
migrate towards the crypt top and then are 
shed into the intestinal lumen (Figure 4)  
(Humphries & Wright 2008; Blanpain et al. 2007; Cernat et al. 2014). Although 
much effort and interest have been spent, the lineage hierarchy and 
proliferative potential of intestinal progenitors still remain under debate (Barker 
et al., 2012). Furthermore, while it is largely acknowledged that the stem cell 
population occupies the crypt base, the origin of the stem cell niche and the 
Figure 4: Architecture of the colon 
epithelium. The colon epithelium is 
separated in different functional 
compartments harboring distinct cell 
lineages. Figure from (Barker, 2014).  
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rational of their fate are still questionable. To provide further insight, lineage 
tracing studies have been established. Thereby single cells are marked 
without changing their features so that the label conveys to the cell’s progeny, 
resulting in clonal expansion of the label. LeBlond and collaborators were the 
first to utilize lineage tracing, examining the intestinal epithelium by pulse-
chase labelling experiments (Bjerknes and Cheng, 1981; Cheng and Leblond, 
1974). They hypothesized that all intestinal cell types originate from intestinal 
stem cells that reside within a small crypt based columnar cell (CBC) 
population at the crypt bottom. Additionally, radiation-damage studies 
challenged this theory, proposing that stem cells seem to be located at the 
forth row from the bottom of the crypt (‘+4’ cells) (Ponder et al., 1985; Potten et 
al., 1997). Using newer approaches of transgenic technologies, Barker and 
colleagues published that the WNT target gene, Leucine repeat-containing G 
protein coupled receptor 5 (Lgr5), is preferentially expressed in cells located at 
the crypt base (Barker et al., 2007; Van de Wetering et al., 2002). Further 
studies revealed additional markers, like Bmi1 (a polycomb RING finger 
oncogene), Tert (telomerase reverse transcriptase), and Hopx (HOP 
homeobox) both of which are preferentially located at position +4 (Montgomery 
et al. 2011; Takeda et al. 2011; Vermeulen & Snippert 2014). Stem cells thus 
may comprise different cell populations that express all four of these markers 
or marker expression may change over time. This led to the question if distinct 
intestinal stem cell populations may coexist or if these markers may not be 
defined by a distinct expression pattern (Buczacki et al., 2013; Itzkovitz et al., 
2012; Muñoz et al., 2012). To answer this question, an inducible labelling 
technique, in which a ubiquitously active promoter controls the expression of a 
Cre transgene, was developed (Lopez-Garcia et al., 2010). Although 
recombination was restricted to epithelial cells within the niche, only those 
cells that appeared to attach to the bottom of the crypt survived long term, and 
subsequently arrange persistent stripes of cells with clonal origin (Figure 5). 
  
Introduction 
 
8 
 
 
The power of an inducible  genetic-labelling approach then was further 
improved by Livet and colleagues, who generated a “Brainbow” multicolor 
reporter transgene that enabled combinatorial expression of different 
fluorescent proteins (XFPs) in a stochastic manner (Livet et al., 2007). Using 
three XFPs, red fluorescent protein (RFP), yellow fluorescent protein (YFP) 
and cyan fluorescent protein (CFP), flanked by three different incompatible lox 
site variants (loxN, lox2272 and loxP), independent recombination of those 
transgene copies allowed generation of distinct color combinations. Cells 
without recombination of this transgene expressed orange fluorescent protein 
(OFP) (Figure 6). Studies like these contributed to a better understanding of 
the architecture of normal colonic mucosa.  
 
 
However, in regards to CRC much less is known since these tumors do not 
preserve the architecture of normal colonic crypts but instead form masses 
with varying degrees of morphologically disarrayed epithelial glands (Bosman 
et al., 2010). However, colon cancers do not appear to be completely 
unorganized. Gradients of less differentiated tumor cells at the leading tumor 
Figure 5: Lineage tracing of the 
intestine: Longitudinal section of 2-week-
old clones. Intestinal cells were 
genetically labelled with a transgenic 
mouse model and a ubiquitous promoter. 
Figure from (Lopez-Garcia et al., 2010). 
  
Figure 6: Brainbow 1.1 construct: Left panel: Construct using three different lox sites, 
generating three recombination possibilities. Right panel: Cells carrying this construct. Cre 
recombination caused expression of M-RFP, M-YFP, or M-CFP. Figure modified from (Livet 
et al., 2007) 
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edge to glandular differentiated tumor cells in the tumor center can be 
observed in many cases, and mimic the polarity of normal colonic crypts to 
varying extent (Brabletz et al., 2001; Cernat et al., 2014). However, compared 
to normal colonic crypts, such gradients in colon cancer are not situated within 
stereotypical morphological units and some colon cancers even lack 
differentiation gradients.  
Colon cancer cell subpopulations with distinct phenotypes and degrees of 
differentiation may have different functions. For example, tumor initiating 
potential has been attributed to a high WNT and MAPK pathway activity 
(Vermeulen et al., 2010; Wang et al., 2010). In well-differentiated colon 
cancers, such tumor cells are frequently located close to the infiltrative tumor 
edge, leading to the hypothesis that colon cancer stem cells reside at this 
location (Brabletz et al., 2005). However, defining colon cancer stem cells 
through tumor-initiating potential, the current “gold standard”, may have certain 
limitations and cannot always be generalized (Horst et al., 2012; Kreso and 
Dick, 2014). Moreover, it has been questioned whether the position of a cell 
within the cellular hierarchy of a growing tumor is adequately reflected by 
tumor-initiating potential (Clevers, 2011). Therefore, from these data, the role 
of distinct tumor cell phenotypes for the dynamics of clonal expansion in colon 
cancer has remained unclear.  
Using similar lineage tracing tools as the ones applied for studies in normal 
colonic mucosa, clonal dynamics in genetically engineered mouse tumor 
models have been analyzed (Driessens et al., 2012; Schepers et al., 2012). 
Moreover, current studies demonstrated clonal outgrowth from colon cancer 
cells with high MAPK activity or expression of the WNT target gene LGR5, and 
thus provided direct evidence for a cellular hierarchy emanating from these 
tumor cell subsets in vivo (Blaj et al., 2017; Shimokawa et al., 2017). Despite 
these data, the role of distinct tumor cell phenotypes in colon cancer still 
remains a subject of debate and needs to be further evaluated. 
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1.4. Epithelial-mesenchymal transition 
 
Further complexity in regard to tumor cell heterogeneity is added by a 
fundamental mechanism described as epithelial-mesenchymal transition 
(EMT) Hereby, epithelial cells lose their distinctive features and become more 
migratory (Figure 7). EMT is thought to be central for cancer invasion and 
considered hallmark of cancer progression (Hanahan and Weinberg, 2011). 
This process was initially observed by Elizabeth Hay as transformations in cell 
structure, that facilitates cells to move into the inner of an embryo and 
contribute to internal organ development (Hay, 1995; Nieto, 2013; Thiery et al., 
2009). The capability of epithelial cells to acquire a mesenchymal state and to 
transform back again in a reverse procedure, called mesenchymal-epithelial 
transition (MET), suggested plasticity of epithelial cell phenotypes (Tam and 
Weinberg, 2013).  
In the process of EMT, epithelial cells lose their polarity, remodulate their 
cytoskeleton which leads to an increased motility that enables the 
transformation into an invasive phenotype (Thiery and Sleeman, 2006; Thiery 
et al., 2009). This is mainly induced by micro environmental signals, leading to 
the activation of transcription factors (TFs) that collaborate with epigenetic 
regulators and therefor change the translation of proteins affecting cell polarity, 
cytoskeleton structure, and extracellular matrix degradation including the 
repression of key epithelial differentiation genes (Tam and Weinberg, 2013).  
The crucial event during EMT is considered to be downregulation of the cell 
adhesion molecule E-cadherin (encoded by CDH1). Additional suppression of 
genes encoding claudins and occludins lead to destabilization of apical tight 
junctions and loss in epithelial barrier function (Huang et al., 2012b; Peinado 
et al., 2007). Furthermore, downregulation of E-cadherin promotes the 
expression of genes that increase mesenchymal adhesion such as neural 
cadherin (N-cadherin) and other markers like LAMC2 or Vimentin (Nieto et al., 
2016; Wheelock et al., 2008). 
On the molecular level, the decrease of E-cadherin expression is mediated by 
transcription factors impairing the CDH1 promoter. They can be classified into 
two groups that either exhibit direct or indirect effects on E-cadherin 
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expression. SNAIL ZEB1, the Krüppel-like factor KLF8 and E47 directly bind 
and  repress  the  activity  of the CDH1 promoter, whereas  factors  such as  
TWIST, the forkhead-box protein FoxC2 and E2.2 repress CDH1 transcription 
indirectly by interacting with miRNAs (Figure 7) (Batlle et al., 2000; Cano et al., 
2000; Gonzalez and Medici, 2014; Huang et al., 2012a; Mani et al., 2007; 
Oliver E. Owen, 2002; Peinado et al., 2007; Pérez-Moreno et al., 2001; 
Sánchez-Tilló et al., 2012; Thiery et al., 2009; Wang et al., 2007; Yang et al., 
2004).  
 
 
 
Figure 7: Molecular mechanisms in the EMT network. In the process of EMT epithelial 
cells (orange, E) transform to mesenchymal cells (green, M). The reverse process termed as 
MET (mesenchymal-epithelial transition). Figure from (Hahn and Hermeking, 2014). 
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Furthermore, it has been shown that mechanisms comparable to EMT can 
also occur as response to injury or during tumorigenesis, in the formation of 
metastasis, and in lesions implicating organ degeneration, such as fibrosis 
(Puisieux, Brabletz, & Caramel, 2014; Arnoux, Nassour, L’Helgoualch, 
Hipskind, & Savagner, 2008; Iwano et al., 2002; Peinado et al., 2007).  
In colorectal cancers, EMT features have been described to occur mainly at 
the invasive edge where tumor cells directly interact with surrounding stromal 
tissue, causing intratumoral gradients of EMT to MET from tumor edge 
towards the differentiated, epithelial tumor center. In addition, the 
mesenchymal phenotype at the invasive edge of the tumor is often 
accompanied by an accumulation of nuclear β-catenin, indicating an active 
WNT pathway (Brabletz, 2012; Brabletz et al., 2005). Moreover, it has been 
shown that the WNT pathway directly induces SNAIL1 activity by 
phosphorylation by GSK3β (Yook et al., 2006; Zhou et al., 2004), linking WNT 
signaling and EMT. Cooperation of other signaling pathways, like Notch, 
MAPK, PI3K-AKT or TGFβ also force the initiation and progression of EMT, 
highlighting the complexity of the EMT signaling network and the importance 
in understanding its fundamental mechanisms to eventually develop potential 
therapeutic strategies.   
 
 
1.5. WNT signaling pathway 
 
WNT signaling is a fundamental pathway found in metazoan animals. WNT 
originates from the Drosophila polarity gene wingless and the vertebrate 
analog, integrated (Wodarz and Nusse, 1998). Signaling through the WNT 
pathway is one of the fundamental mechanisms affecting cell polarity, 
proliferation and embryonic development (Logan and Nusse, 2004). Hence, 
alterations in this pathway often cause human birth defects, neurological 
disorders and various cancers (Clevers, 2006; Clevers and Nusse, 2012; De 
Ferrari and Moon, 2006). 
WNTs are secreted proteins that are encoded by 19 different genes in the 
human genome. These proteins are characterized by a similar sequence 
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pattern that encodes for proteins with a distinct cysteine pattern and further 
conserved residues, instead of functional features. With more than 15 
different receptors and co-receptors the WNT pathway accounts for a 
signaling cascade that is extremely complex and often regulated by feed-back 
control (Miller, 2002). 
The crucial event of the canonical or WNT/β-catenin signaling pathway is the 
translocation of the adherens junction associated protein β-catenin into the 
nucleus (Figure 8). If WNT is absent, cytoplasmic β-catenin is continuously 
phosphorylated from the β-catenin destruction complex, that includes the 
scaffolding protein Axin, the tumor suppressor adenomatous polyposis coli 
gene product (APC), casein kinase 1 (CK1), and glycogen synthase kinase 3 
β (GSK-3β) (Amit et al., 2002; Liu et al., 2002; Yanagawa et al., 2002; Yost et 
al., 1996). Together, this inhibits that β-catenin translocates into the nucleus 
and represses the expression of WNT target genes by the T cell 
factor/lymphoid enhancer factor (TCF/LEF) (Aberle et al., 1997). 
If a WNT ligand is present, the low-density lipoprotein receptor related 
proteins 5/6 (LRP5/6), form complexes with WNT-bound Frizzled, leading to 
the activation of the scaffolding protein Dishevelled (Dvl). A following 
displacement of GSK-3β from APC/Axin results in the recruitment of the 
destruction complex to receptors, thus inhibiting Axin-mediated β-catenin 
phosphorylation. This increase of β-catenin levels leads to its nuclear 
accumulation, replaces Groucho from TCF/LEF and activates the transcription 
of WNT target genes (Clevers, 2006; Gammons et al., 2016; Li et al., 2012). 
The importance of altered WNT/β-catenin signaling in cancer, particularly in 
CRC is well documented. Although WNT is constitutively active, due to 
inactivating mutations in APC or activating β-catenin mutations, WNT 
signaling in CRC still remains regulated on high levels, leading to different 
tumor cell populations with low or high WNT activity (Horst et al., 2012). It has 
been shown that colon cancer cell subpopulations harboring high levels of 
WNT activity are typically associated with mesenchymal characteristics such 
as putative cancer stem cell traits and a marker expression profile that is 
linked to tumor invasion (Brabletz et al., 2005). These cells reside at the 
infiltrative tumor edge where they can invade the surrounding tissue. On the 
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contrary, cells with low WNT signaling commonly occupy the center of the 
tumor (Cernat et al., 2014; Kirchner and Brabletz, 2000). Due to these 
findings, high WNT signaling activity is assumed to be a driving force of colon 
cancer invasion and progression, making it an attractive potential target for 
therapeutic intervention (Kahn, 2014).        
   
  
Figure 8: Summary of the WNT signaling pathway. (A) In the absence of WNT, β-catenin 
binds to the deconstruction complex that leads its degradation. (B) WNTs bind to their 
receptors resulting in an inactivation of GSK3β and further to an activation of WNT target 
genes by β-catenin. Figure from (Staal and Clevers, 2005). 
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1.6. Pre-B-cell leukemia transcription factor 3 
 
Distinct degrees of EMT and WNT signaling in colon cancer exemplify that 
colorectal cancers are composed of phenotypically different cell 
subpopulations in the same genetic background. In the second part of this 
thesis, we searched for unknown factors that are associated with tumor cell 
heterogeneity. In this context, we identified high expression of the TALE 
transcription factor Pre-B-cell leukemia homeobox transcription factor 3 
(PBX3) in tumor cells undergoing EMT. PBX3 belongs to a transcription factor 
family that is described to facilitate tumor growth. Enhanced expression of 
PBX3 is associated with tumor growth and progression in various cancer 
types like ovarian cancer, melanoma and prostate cancer (H.-B. Han et al., 
2014; Crijns et al., 2007; Kikugawa et al., 2006; Shiraishi et al., 2007). 
Although some research has been done on the other PBX homologues, the 
biological function of PBX3 remains unknown  ( Y. Li et al., 2014; Monica, 
Galili, Nourse, Saltman, & Cleary, 1991). Recently, it has been shown in 
prostate and colorectal cancer that PBX3 was upregulated and the expression 
was mediated by androgen through micro RNA let-7d (Han et al., 2012; 
Ramberg et al., 2011). Furthermore, other studies revealed a correlation of 
high PBX3 expression with the invasiveness of CRC cells and an association 
with metastasis (Han et al., 2014). However, the contribution of PBX3 to 
human colorectal cancer and its functional role in tumor progression has 
remained unclear. 
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2. Aims of the thesis 
 
 
 
 
This thesis had the following aims: 
 
 
 
I)  Determination of the clonal architecture and dynamics in colon cancer  
 
 
II) Identification and characterization of PBX3 expression in colorectal 
cancer 
 
 
 
Materials 
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3. Materials 
 
3.1. Chemicals and reagents 
Compound Supplier 
4-Hydroxytamoxifen ≥70% Z isomer (remainder 
primarily E-isomer) Sigma-Aldrich, St. Louis, MO, USA 
4x Laemmli Sample Buffer Bio-Rad, München, Germany 
All purpose Hi-Lo DNA Marker Bionexus, Netanya, Israel 
Agarose Biozym LE Biozym Scientific GmbH, Hessisch Oldendorf, Germany 
Ampicillin sodium salt Sigma-Aldrich, St. Louis, MO, USA 
APS (ammonium peroxodisulfate) Carl Roth GmbH, Karlsruhe, Germany 
beta-Mercaptoethanol Carl Roth GmbH, Karlsruhe, Germany 
Biofreeze Biochrom GmbH, Berlin, Germany 
Blasticidin Carl Roth GmbH, Karlsruhe, Germany 
BSA (Albumin Faktor V) Carl Roth GmbH, Karlsruhe, Germany 
BSA Standard Set                                                                              Bio-Rad, Munich, Germany 
Bovine serum albumin 25% (BSA) Thermo Fisher Scientific Inc., Waltham, MA, USA 
Chloramphenicol Carl Roth GmbH, Karlsruhe, Germany 
Chlorophorm Sigma-Aldrich, St. Louis, MO, USA 
cOmplete mini protease inhibitor cocktail Roche Diagnostics GmbH, Mannheim, Germany 
DAPI (2-(4-amidinophenyl)-6-indolecarbamidine 
dihydrochloride) Carl Roth GmbH, Karlsruhe, Germany 
dNTPs (deoxynucleotides triphosphate) Thermo Fisher Scientific Inc., Waltham, MA, USA 
DMEM Biochrom GmbH, Berlin, Germany 
DMEM/F-12 with GlutaMAX medium Thermo Fisher Scientific Inc., Waltham, MA, USA 
DMSO (dimethyl-sulfoxide) Carl Roth GmbH, Karlsruhe, Germany 
dNTP Mix                                                                                            Thermo Fisher Scientific Inc., Waltham, MA, USA 
Doxycycline hyclate Sigma-Aldrich, St. Louis, MO, USA 
ECL/HRP substrate Immobilon, Merck Millipore, Billerica, MA, USA 
EGF Recombinant Human Protein Thermo Fisher Scientific Inc., Waltham, MA, USA 
Ethidiumbromidlösung 1% Carl Roth GmbH, Karlsruhe, Germany 
Fast-Media Amp Agar InvivoGen, San Diego, CA, USA 
Fast SYBR Green Master Mix Applied Biosystems, Foster City, CA, USA 
FBS (fetal bovine serum) Biochrom GmbH, Berlin, Germany 
FGF-Basic  Recombinant Human Protein Thermo Fisher Scientific Inc., Waltham, MA, USA 
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Compound Supplier 
FuGENE6 Transfection Reagent Promega, Madison, WI, USA 
GE Healthcare Chromatography Paper  Schubert & Weiss Omnilab GmbH & Co. KG, München, Germany 
Hi-Di Formamide Applied Biosystems, Foster City, CA, USA 
HiPerFect Transfection Reagent Qiagen GmbH, Hilden, Germany 
ImmEdge Hydrophobic Barrier PAP Pen Biozol GmbH, Eching, Germany 
Immobilon-P Transfer Membrane Immobilon, Merck Millipore, Billerica, MA, USA 
LB medium (Luria/Miller) Carl Roth GmbH, Karlsruhe, Germany 
LipoD293 Tebu-Bio, Le Perray En Yvelines, France 
Matrigel Corning, New York City, NY, USA  
NP40 Substitute Sigma-Aldrich, St. Louis, MO, USA 
Opti-MEM Thermo Fisher Scientific Inc., Waltham, MA, USA 
PageRuler Plus Prestained Protein Ladder  Fermentas GmbH, St. Leon-Rot, Germany 
Paraformaldehyde Carl Roth GmbH, Karlsruhe, Germany 
Penicillin/Streptomycin Biochrom GmbH, Berlin, Germany 
PhosSTOP Phosphatase Inhibitor Ccocktail Roche Diagnostics GmbH, Mannheim, Germany  
ProLong Gold Antifade  Invitrogen GmbH, Karlsruhe, Germany 
Propidium iodide Sigma-Aldrich, St. Louis, MO, USA 
Puromycin dihydrochloride Merck KGaA, Darmstadt, Germany 
Rotiphorese Gel 30 (37,5:1) Carl Roth GmbH, Karlsruhe, Germany 
SDS (sodium dodecyl sulfate) Carl Roth GmbH, Karlsruhe, Germany 
Skim milk powder Sigma-Aldrich, St. Louis, MO, USA 
sunflower oil Sigma-Aldrich, St. Louis, MO, USA 
StemPro hESC Supplement Thermo Fisher Scientific Inc., Waltham, MA, USA 
Tamoxifen free base Sigma-Aldrich, St.Louis, MO, USA 
Target Retrieval Solution 6 (TRS) Agilent Technologies, Inc., Santa Clara, CA, USA 
Temed (tetramethylethylendiamin,1,2-bis 
(dimethylamino) -ethan) Carl Roth GmbH, Karlsruhe, Germany 
Triton X 100 Carl Roth GmbH, Karlsruhe, Germany 
Trizol Reagent Invitrogen GmbH, Karlsruhe, Germany 
Trypsin/ EDTA solution  Biochrom GmbH, Berlin, Germany 
Tween 20 Sigma-Aldrich, St. Louis, MO, USA 
WNT3a                                                                                                  R&D Systems, Minneapolis, MN, USA 
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3.2. Enzymes 
Enzyme Supplier 
DNAse I (RNAse-free) Sigma-Aldrich, St. Louis, MO, USA 
FastAP Thermosensitive Alkaline Phosphatase Thermo Fisher Scientific Inc., Waltham, MA, USA 
FIREPol DNA Polymerase Solis BioDyne, Tartu, Estonia 
Klenow Fragment Thermo Fisher Scientific Inc., Waltham, MA, USA 
Pfu Polymerase (recombinant) Thermo Fisher Scientific Inc., Waltham, MA, USA 
Proteinase K Thermo Fisher Scientific Inc., Waltham, MA, USA 
T4 DNA polynucleotide kinase Thermo Fisher Scientific Inc., Waltham, MA, USA 
 
 
3.3. Kits 
Kit Supplier 
DyeEx 2.0 Spin Kit QIAGEN GmbH, Hilden, Germany 
Pure Yield Plasmid Midiprep System Promega GmbH, Mannheim, Germany 
QIAprep Spin Miniprep Kit QIAGEN GmbH, Hilden, Germany 
Quantitect Reverse Transcription Kit QIAGEN GmbH, Hilden, Germany 
QuikChange II XL Site-Directed Mutagenesis Kit Stratagene, Agilent Technologies GmbH & Co.KG, Waldbronn, Germany 
RevertAid H Minus First Strand cDNA Synthesis 
Kit Thermo Fisher Scientific, Inc., Waltham, MA, USA 
Vectastain ABC Kit Universal Vectorlabs, Burlingame, CA, USA 
Wizard SV Gel and PCR Clean-Up System Promega GmbH, Mannheim, Germany 
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3.4. Antibodies 
 
3.4.1. Primary antibodies 
Antigen Source/Clone Application Supplier 
α-tubulin Mouse/ DM 1A WB Sigma-Aldrich, St. Louis, MO, USA 
Active- β-
catenin Mouse/ 8E7 WB Merck KGaA, Darmstadt, Germany 
β-catenin Mouse/ clone 14 IHC Ventana Medical Systems, Oro Valley, AZ, USA 
β-catenin Mouse WB BD PharMingen, Heidelberg, Germany 
BrdU Mouse IHC Santa Cruz Biotechnology, Inc., Heidelberg, Germany 
CK20 Goat IHC, IF Santa Cruz Biotechnology, Inc., Heidelberg, Germany 
Cre Rabbit WB Cell Signaling Technology, Inc., Danvers, MA, USA 
FLAG Rabbit IHC, IF Cell Signaling Technology, Inc., Danvers, MA, USA 
FRA-1 Rabbit IHC, IF Abcam, Cambridge, UK 
E-cadherin Mouse/ 24E10 WB, IF Cell Signaling Technology, Inc., Danvers, MA, USA 
GFP Mouse/ 4B10 IF Cell Signaling Technology, Inc., Danvers, MA, USA 
GLUT1 Mouse/ A-4 IHC, IF Santa Cruz Biotechnology, Inc., Heidelberg, Germany 
Ki67 Rabbit IHC Cell Signaling Technology, Inc., Danvers, MA, USA 
Laminin5γ2 Mouse/ D4B5 IHC Merck Millipore KGaA, Darmstadt, Germany 
PBX3 Mouse/ M01 WB, IHC, IF Abnova, Taipei, Taiwan 
Snail Rabbit WB, IF Cell Signaling Technology, Inc., Danvers, MA, USA 
V5 Goat IHC, IF Abcam, Cambridge, UK 
VSV Rabbit/ P5D4 IHC, IF Abcam, Cambridge, UK 
Vimentin Rabbit WB Cell Signaling Technology, Inc., Danvers, MA, USA 
ZEB1 Rabbit/ H-102 WB Santa Cruz Biotechnology, Inc., Heidelberg, Germany 
WB: Western blot analysis, IF: immunofluorescence, IHC: immunohistochemistry   
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3.4.2. Secondary antibodies 
Name Source/Clone Application Supplier 
Anti-Rabbit HRP Goat WB Sigma-Aldrich, St. Louis, MO, USA 
Anti-Mouse HRP Donkey WB Promega GmbH, Mannheim, Germany 
Anti-Goat Alexa Fluor 
488 Donkey IF 
Thermo Fisher Scientific, 
Inc., Waltham, MA, USA 
Anti-Mouse Alexa 
Fluor 568 Donkey IF Abcam, Cambridge, UK 
Anti-Rabbit Alexa 
Fluor 568 Donkey IF Abcam, Cambridge, UK 
Phalloidin-Alexa-568 - IF Thermo Fisher Scientific, Inc., Waltham, MA, USA 
WB: Western blot analysis, IF: immunofluorescence 
 
 
3.5. DNA constructs and oligonucleotides 
 
3.5.1. Template vectors 
Name Insert Reference 
CMV-Brainbow Kusabira Orange, mCherry, mEYFP, M-mCerulean (Livet et al., 2007) 
pBV-luc  (He et al., 1999) 
pBV-PBX3 PBX3 - promoter  
PBX3 geneblock 
human PBX3 3'UTR from -2674 to 
-1185 relative to the translational 
start site  
 
pCMV-dR8.91 Gag-Pol (Zufferey et al., 1997) 
pLenti CMV rtTA3G Blast Reverse Tetracycline transactivator 3G Dominic Esposito 
pLenti CMVTRE3G eGFP Puro Enhance Green Fluorescent Protein Eric Campeau 
pMD2.G VSV G Didier Trono 
pRTR  (Jackstadt et al., 2013) 
pRTR-Snail human Snail  (Siemens et al., 2011) 
pRTR-ZEB1 human ZEB1   
pGL3-control-MCS  (Kaller et al., 2011; Welch et al., 2007) 
pGL3-PBX3 wt human PBX3 3'UTR  
pGL3- PBX3 mut human PBX3  3'UTR  
pRL Renilla (Pillai, 2005) 
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3.5.2. Primers 
Gene Sequence (5’ – 3’) Purpose 
Axin 2 fwd AGGCCAGTGAGTTGGTTGTC qPCR 
Axin 2 rev CATCCTCCCAGATCTCCTCA qPCR 
CTNNB1 fwd AGCTGACCAGCTCTCTCTTCA qPCR 
CTNNB1 rev CCAATATCAAGTCCAAGATCAGC qPCR 
CDH1 fwd ATCCAAAGCCTCAGGTCATA qPCR 
CDH1 rev CAGCAAGAGCAGCAGAAT qPCR 
CreERT2 fwd ATCCACCTGATGGCCAAG qPCR 
CreERT2 rev GCTCCATGCCTTTGTTACTCA qPCR 
GAPDH fwd ACCACAGTCCATGCCATCAC qPCR 
GAPDH rev TCCACCACCCTGTTGCTGTA qPCR 
LGR5 fwd TACCCACAGAAGCTCTGCAGAATT qPCR 
LGR5 rev TGTTCAGGGCCAAGGTCATG qPCR 
NKD-1 fwd TCACTCCAAGCCGGCCGCC qPCR 
NKD-1 rev TCCCGGGTGCTTCGGCCTATG qPCR 
PBX3 fwd GCCTTGGAGGAAATTCACTG qPCR 
PBX3 rev AGATGGAGTTGTTGCGTCCT qPCR 
PBX3 3'UTR fwd TAAGAATTCGATCAGAGACTGGTAGCATCG PCR 
PBX3 3'UTR rev ATAACCGGTAATCATGAAAGCAAAAAGTTTATTC PCR 
PBX3 3'UTR mut fwd GAAATATACAGTACTGAAAAGTCAAATCTGAATGCATCACAATTAGTCGCTGCTTTT PCR 
PBX3 3'UTR mut rev AAAAGCAGCGACTAATTGTGATGCATTCAGATTTGACTTTTCAGTACTGTATATTTC PCR 
PBX3 5'UTR fwd CTCTAAGCGCTTTGCGATTG PCR 
PBX3 5'UTR rev AGCATCCTGGATTGATCGTC PCR 
pri-miR-200c fwd CTTAAAGCCCCTTCGTCTCC qPCR 
pri-miR-200c rev AGGGGTGAAGGTCAGAGGTT qPCR 
Snail fwd GCACATCCGAAGCCACAC qPCR 
Snail rev GGAGAAGGTCCGAGCACA qPCR 
Vimentin fwd TACAGGAAGCTGCTGGAAGG qPCR 
Vimentin rev ACCAGAGGGAGTGAATCCAG qPCR 
ZEB1 fwd TCAAAAGGAAGTCAATGGACAA qPCR 
ZEB1 rev GTGCAGGAGGGACCTCTTTA qPCR 
fwd = forward, rev = reverse, PCR = polymerase chain reaction, qPCR = quantitative 
(real time) reverse transcription PCR,  
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3.5.3. siRNAs and MicroRNA mimics 
 
Scramble siRNA, β-Cat siRNA1 and β-Cat siRNA2 were purchased from 
QIAGEN. pre-miR-200c, siRNAs against PBX3 and ZEB1 were obtained from 
Ambion. 
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3.6. Buffers and solutions 
 
50x TAE buffer 
 
• 40 mM Tris Base 
• 20 mM acetic acid 
• 1 mM EDTA pH 8.0 
• ad 1 liter ddH2O 
 
 
10x Vogelstein‘ PCR buffer: 
 
§ 166 mM NH4SO4     
§ 670 mM Tris (pH 8.8)     
§ 67 mM MgCl2     
§ 100 mM β-mercaptoethanol   
 
 
RIPA buffer (for protein lysates): 
 
• 1% NP40 
• 0.5% sodium deoxycholate 
• 0.1% SDS 
• 150 mM NaCl  
• 50 mM TrisHCl (pH 8.0)  
• ad 100 ml ddH2O 
 
 
10x Tris-glycine-SDS running buffer: 
 
• 1.92 M  glycine  
• 250 mM Tris base  
• 1% SDS  
• pH 8.3-8.7 
• ad 5 liters ddH2O 
 
 
10x Transfer buffer: 
 
• 1.92 M  glycine  
• 250 mM Tris base  
• 1% SDS  
• pH 8.3-8.7 
• 25% Methanol 
• ad 1 liter ddH2O 
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10x TBS: 
• 20  mM Tris base  
• 150 mM NaCl 
• ad 5 liters ddH2O 
 
 
1x TBST (10l): 
 
• 20  mM Tris base  
• 150 mM NaCl 
• 0.1% Tween 20 
• ad 10 liters ddH2O 
 
 
Cell culture medium completed: 
 
• 500 ml DMEM  
• 10% FCS 
• 1% Penicillin/Streptomycin 
 
 
Freezing medium: 
 
• FCS 
• 10% DMSO  
 
 
 
TRIS buffer: 
 
• 1 M Tris base  
• pH 7.4 
• ad 1 liter ddH2O 
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3.7. Laboratory equipment 
Device Supplier 
5415R table-top centrifuge  Eppendorf AG, Hamburg, Germany 
ABI 3130 genetic analyzer capillary sequencer Applied Biosystems, Foster City, USA 
Axioplan 2 Carl Zeiss GmbH, Oberkochen, Germany 
Axiovert 25 microscope  Carl Zeiss GmbH, Oberkochen, Germany 
BD Accuri C6 Flow Cytometer Instrument Accuri, Erembodegem, Belgium 
BD FACSAria III Becton Dickinson, Franklin Lakes, NJ, USA  
CF40 Imager  Kodak, Rochester, New York, USA 
Falcons, dishes and cell culture materials Schubert & Weiss OMNILAB GmbH & Co. KG 
Fisherbrand FT-20E/365 transilluminator Fisher Scientific GmbH, Schwerte, Germany 
Forma scientific CO2 water jacketed incubator Thermo Fisher Scientific, Inc., Waltham, MA, USA 
GeneAmp PCR System 9700  Applied Biosystems, Foster City, USA 
HERACell 240i Co2 Incubator Thermo Fisher Scientific, Inc., Waltham, MA, USA 
Herasafe 2020 safety cabinet Thermo Fisher Scientific, Inc., Waltham, MA, USA 
HTU SONI130  G. Heinemann Ultraschall- und Labortechnik, Schwäbisch Gmünd, Germany 
Light Cycler 480 II Hoffmann-La Roche AG, Basel, Schweiz 
LSM 700 Carl Zeiss GmbH, Oberkochen, Germany 
ME2CNT membrane pump Vacuubrand GmbH & CO KG, Wertheim, Germany 
Megafuge 1.0R Heraeus; Thermo Fisher Scientific, Inc., Waltham, MA, USA 
Mini-PROTEAN-electrophoresis system Bio-Rad, München, Germany 
MultiImage Light Cabinet  Alpha Innotech, Johannesburg, South Africa 
ND 1000 NanoDrop Spectrophotometer NanoDrop products, Wilmington, DE, USA 
Neubauer counting chamber  Carl Roth GmbH & Co, Karlsruhe, Germany 
Orion II luminometer Berthold Technologies GmbH & Co. KG, Bad Wildbad, Germany 
Peqpower Peqlab Biotechnologie GmbH, Erlangen, Germany 
PerfectBlue SEDEC 'Semi-Dry' blotting system  Peqlab Biotechnologie GmbH, Erlangen, Germany 
Primo Vert microscope Carl Zeiss GmbH, Oberkochen, Germany 
T100 Thermo Cycler Bio-Rad, München, Germany 
Thermoblock comfort Eppendorf AG, Hamburg, Germany 
Varioskan Flash Multimode Reader Thermo Scientific, Inc., Waltham, MA, USA 
Waterbath Memmert GmbH, Schwabach, Germany 
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4. Methods 
 
4.1. Bacterial cell culture 
 
Standard cloning procedures were carried out using Stbl3 and Dh5α bacterial 
E.coli strains (Invitrogen). Bacteria were cultured at 37°C overnight in LB 
medium or on LB agar plates to isolate single cell colonies. Resistant clones 
bearing a resistance cassette were selected by addition of ampicillin (100 
µg/ml).  
Plasmid transformation into bacteria was achieved by adding 100 ng of 
plasmid DNA into competent E.coli followed by a 30 minutes incubation step 
on ice. After 90 seconds of heat shock at 42°C cells were placed on ice for 
another two minutes and then plated on ampicillin containing LB-agar plates 
at 37°C overnight. To extract plasmid DNA, single clones of the bacterial 
cultures were cultivated in ampicillin containing LB-medium for 8-12 hours and 
QIAprep Spin Miniprep Kit (Qiagen) was used. 
To identify and determine the orientation of bacterial clones harboring a vector 
insert, single clones were collected and a colony PCR was performed. Finally, 
PCR products were visualized on a 1% agarose gel. For amplification of 
plasmid DNA, 50 ng DNA was transferred into a 40 µl reaction mix containing 
1 µl dNTPs, 4 µl 10x PCR buffer, 2 µl DMSO, 1 µl Pfu DNA polymerase and 1 
µl of forward and reverse primers each. PCR cycling conditions were as 
exemplarily given: three minutes at 95°C, followed by 30 cycles of 95°C for 30 
seconds, 60°C for 90 seconds, 72°C for 30 seconds and a termination cycle for 5 
minutes at 72°C. 
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4.2. Mammalian cell culture 
 
4.2.1. Cultivation of human cell lines 
 
Colo320, DLD-1, HEK293, HCT116, LS174T, LoVo, SW620 and SW480 cell 
lines were obtained from ATCC, SW1222 were a gift from the Ludwig Institute 
for Cancer Research (New York, USA). LS174T dnTCF4 and DLD-1 dnTCF4 
were a kind gift from M. van de Wetering (Hubrecht Institute, Utrecht; (Van de 
Wetering et al., 2002)). Cells were cultured in Dulbecco’s Modified Eagle’s 
Medium (DMEM) completed with 10% fetal bovine serum (FBS), 100 U/ml 
penicillin, and 0.1 mg/ml streptomycin at 37°C and 5% CO2. For induction 
experiments, doxycycline (DOX) was always used at a concentration of 100 
ng/ml.  
	
 
4.2.2. Generation of DNA constructs	
 
The pRTR-ZEB1-VSV vector was generated by an excision of  the ZEB1 
cDNA from pcDNA-His-MaxC-ZEB1 (a kind gift from Janet E. Mertz, McArdle 
Laboratory for Cancer Research, University of Wisconsin School of Medicine 
and Public Health; (Ellis-Connell et al., 2010)) with NotI and XbaI and cloned 
into pUC19-SfiI. The DNA sequence encoding the N-terminal His-tag was 
excised with NotI and BamHI and replaced by complementary 
oligonucleotides encoding a VSV-tag. The VSV-ZEB1 encoding sequence 
was then excised with SfiI and cloned into pRTR (Jackstadt et al., 2013).  
The pRTR-SNAIL-VSV vector has been described recently (Siemens et al., 
2011). Hereby cells were transfected with the pRTR expression vector using 
Fugene6. Afterwards positive cells were selected with 2 µg/ml Puromycin for 
two weeks. Transfection efficiency was checked by adding DOX at a final 
concentration of 100 ng/ml and counting GFP-positive cells. 
Cloning of the PBX3 3'-UTRs with putative miR-200c binding sites was done 
by PCR amplification of the human PBX3 mRNA from SW480 cells using Pfu 
Polymerase. The obtained PBX3 mRNA sequences were inserted into pGL3-
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control vector. Mutation of the miR‑200 binding sequences of human PBX3 
3'UTRs was done with the QuickChange Mutagenesis Kit (Stratagene) and 
checked by sequencing.  
For analysis of WNT/β-catenin activity within the PBX3 promotor, 2500 bp 5’ 
of the PBX3 transcription start site were obtained by PCR amplification from a 
human BAC clone (Life technologies) using Pfu Polymerase. The obtained 
promoter sequences were inserted into pBV luc-control vector. Synthetic DNA 
sequences (IDT) were used to replace TCF4 binding sites by mutated sites 
and checked by sequencing. 
For the inducible pLenti TetO-CreERT2 expression vector, we PCR amplified 
CreERT2 from pCAG-CreERT2 (Diaz Jr et al., 2012), and inserted it between 
BamH1 and Xba1 restriction sites of pLenti CMVTRE3G eGFP Puro (a gift 
from Eric Campeau), replacing eGFP by CreERT2. For the Cre sensitive 
recombination vector pLenti Multicolor, we first PCR-amplified expression 
cassettes for Kusabira orange, mCherry, and EYFP from CMV-Brainbow 1.1 
M (Gatenby et al., 2009), and EBFP2 from pEBFP2-Nuc (Matsuda and 
Cepko, 2007), using primers that omitted membrane or nuclear localization 
signals, respectively. Amplicons then were inserted into EcoRV sites of 
pcDNA3.1(+) (Invitrogen), and the 3’ ends of mCherry, EYFP, and EBFP2 
were replaced from BsrG1 to Not1 restriction sites by synthetic sequences 
that added FLAG, V5, or VSV tags, respectively. Kusabira orange and tagged 
fluorescent color coding genes then were sequentially inserted into a plasmid 
with synthetic paired loxN, lox2272, and loxP sites. The whole expression 
cassette then was inserted between Age1 and Sal1 sites of pLenti PGK-GFP 
(a gift from Didier Trono), replacing GFP. Finally, the PGK promoter was 
replaced by an EF1α promoter, yielding pLenti Multicolor. To check DNA 
sequences of all vectors, samples were sent to GATC Biotech for Sanger 
sequencing. 
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4.2.3. Lentivirus production 
 
Lentivirus was produced in HEK293 cells that had been seeded 24 hours 
before by co-transfection of 10 µg of the lentiviral vector with 10 µg pCMV-
dR8.91, and 2 µg pMD2.G using 60 µl LipoD293. After 15 minutes of 
incubation the transfection mix was added drop-wise to unsupplemented 
DMEM. After 12 hours, the medium was changed with fresh completed 
DMEM. 36 hours post transfection, the virus containing culture supernatant 
was collected, and given on pre cultured CRC cell lines for infection. HCT116 
and SW1222 cells were sequentially stably transduced with pLenti CMV 
rtTA3G Blast and pLenti TetO-CreERT2. Cells were then selected with 
puromycin and blasticidin, and subsequently infected with pLenti Multicolor. 
After 3-5 days, cells with orange fluorescence were single cell subcloned by 
limiting dilution and expanded. To test recombination in vitro, CreERT2 
expression was induced in cells by 1 µg/ml DOX for 4 days, and 
recombination was induced with 10 µM 4-hydroxytamoxifen. After 3-10 days, 
cells were inspected by fluorescence microscopy. 
 
 
4.2.4. Transfection of siRNAs and plasmids 
 
Transient transfections with Individual synthesized siRNAs were carried out 
using a transfection mix containing 250 µl Opti-MEM, 6 µl HiPerFect and 6 µM 
of oligonucleotide obtaining a final concentration of 100 nM, was set up. For 
pre-miR-200c 30 nM and WNT3a 20ng/ml were used, respectively. After 15 
minutes of incubation, the transfection mix was given slowly to the cells. 
Transfection of reporter plasmids in a 100 mm dish was carried out using 4 µg 
DNA and 5 µl FuGENE in a 300 µl transfection master mix. 
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4.3. Tumor xenografts and in vivo treatments 
 
Mouse experiments were reviewed and approved by the Regierung von 
Oberbayern. 106 single clone expanded SW1222 or HCT116 colon cancer 
cells, carrying the multicolor lineage tracing constructs, were suspended in 
100 µl of a 1:1 mixture of PBS and growth factor-depleted Matrigel (Corning), 
and injected subcutaneously into 6-8 week old NOD/SCID mice (NOD.CB17-
Prkdcscid, The Jackson Laboratory) for xenograft formation. When tumor 
diameters reached 7 mm, recombination of pLenti Multicolor transgenes was 
induced by 1 mg doxycycline p.o. for 3 consecutive days, followed by 3 mg 
tamoxifen i.p. (Sigma Aldrich). Mice were sacrificed and tumors were removed 
at 3, 10, 17, 24, or 31 days after induction. For BrdU tracing, mice were 
injected once with a 1.25 mg BrdU pulse. At distinct time points mice killed, 
tumors were removed, fixed in formalin and embedded in paraffin for further 
analyses. 
 
 
4.4. RNA Isolation , reverse transcription and qPCR 
 
RNA was collected with Trizol Reagent. Next, cDNA for each probe was 
synthesized from 500 ng RNA using the Reverse Transcription Kit. qPCR was 
carried out by using a LightCycler 480 and SYBR Green Master Mix applying 
40 cycles of amplification at 95°C (1 sec), 60°C (20 sec), and 72 °C (1 sec). 
Obtained results were then assigned by normalization to the mRNA levels of 
the house-keeping gene GAPDH. Primer specificity was checked by recording 
a melting curve for the PCR products. For sequences of oligonucleotides used 
as qPCR primers see 3.5.2. 
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4.5. Protein isolation and Western blot analysis 
 
For Western Blotting, cells were cultured under indicated conditions, 
harvested and resuspended in RIPA buffer with protease- and phosphatase-
inhibitors. The cell lysate was further sonicated for ten seconds and then 
separated by centrifugation for 15 minutes at 14.000 g at 4°C. 
Protein concentrations were measured in a Varioskan Plate Reader using the 
BSA Standard Set. 50 µg of protein diluted in Laemmli buffer were then 
denatured for 5 minutes at 95°C, and loaded on a 10% SDS- acrylamide Gel. 
Gel electrophoresis was carried out at 120 V in an electrophoresis system 
using a Tris-glycine-SDS running buffer. Transfer of the proteins form the Gel 
to an Immobilon-P PVDF membrane was done, using a 'Semi-Dry' blotting 
system at a constant current of 120 mA and 10 V for around 90 minutes. To 
avoid nonspecific binding of the primary antibodies the membrane was 
incubated in 5% skim milk/TBS-T for at least 60 minutes. Antibodies were 
diluted in BSA and applied at 4°C over-night. After extensive washing with 
TBS-T membranes were incubated in diluted horseradish-peroxidase (HRP)-
conjugated antibodies for 60 minutes. For detection of protein bands the 
membrane was incubated with an ECL/HRP substrate and signals were 
detected by an Imager (Kodak). Applied Antibodies are listed in the table in 
chapter 3.4. 
 
 
4.6. Luciferase assay 
 
HEK293T, Colo320 and SW480 cells were transfected in 24-well plates using 
50 ng of a firefly luciferase reporter plasmid, 10 ng of the Renilla reporter 
plasmid and 20 ng/mL of WNT3a, or 30 nM of pre-miR-200c. 48 hours later, 
the intensity of the luciferase activity was detected with an Orion II 
luminometer and further analyzed with the SIMPLICITY software. 
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4.7. Immunofluorescence and Immunohistochemistry 
 
Immunohistochemical staining was performed using 5µm sections as 
previously described (Brabletz et al., 2001). Deparaffinization was achieved 
by xylol and ethanol and antigen retrieval was done in a pH6 buffer for 20 min. 
Next, the sections were stained with primary antibodies on a Ventana 
Benchmark XT autostainer with Universal DAB and alkaline phosphatase 
detection kits.  
Stained slides then were inspected by light microscopy for the distribution of 
each marker-antigen and categorized as negative, polarized if expression 
gradients from leading tumor edge to tumor center were observed, or diffuse if 
such gradients were absent. Ki67 proliferation was separately assessed at the 
leading tumor edge and in the tumor center. Relative BrdU staining intensity 
was quantified continuously from leading tumor edge to tumor center using 
ImageJ (NIH). 
For immunofluorescent staining, cells were cultivated under respective 
conditions. Slides or cover-slips were then consecutively stained for 60 
minutes with primary antibodies and subsequently secondary Alexa Fluor 405, 
488 or 555 conjugated antibodies were used for visualization, and nuclei were 
counterstained with DAPI. An Alexa Fluor 647-labeled Phalloidin antibody was 
applied to detect stress fiber forming F-actin. Images were taken on a LSM 
700 laser scanning microscope using a Plan Apochromat 20x/0.8 M27 
objective and the ZEN 2009 software (Zeiss). Antibodies used are listed un 
3.4. 
 
 
4.8. Clinical case collections 
 
Samples of colorectal cancer patients that underwent intentionally surgical 
resection between 1994 and 2006 at the LMU were obtained from the 
archives of the institute of pathology. Follow-up data were documented 
prospectively by the tumor registry Munich. This collection was assembled 
respectively to the guidelines of the ethics committee of the Medical Faculty of 
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the LMU. For the survival collection, inclusion criteria were localized UICC 
stage II colorectal cancers. Finally, the collection consisted of 244 colorectal 
cancer samples of which in 52 (21.3%) patients had died of their tumor within 
the follow-up period. Survival data were censored when case follow-up was 
discontinued or when patients had died of reasons other than colorectal 
cancer. For the metastasis collection a case control design was chosen and 
tumor specimens of 90 patients with right sided colon cancers were included. 
Half of the patients had colon cancers with synchronous liver metastasis, 
where metastasis were diagnosed by clinical imaging or liver biopsy. Controls 
consisted of colon cancer patients without distant metastasis at the time of 
diagnosis and with a disease-free survival of at least 5 years after primary 
surgical resection. Cases and controls were matched by tumor grade 
(according to WHO 2010) and T-category, resulting in 45 matched pairs. Of 
both collections tissue microarrays (TMAs) were generated with 6 
representative 1 mm cores of each case. 
 
 
4.9. Gene expression datasets and GSEA 
 
For comparative analyses of tumor cell subpopulations, three gene 
expression data sets derived from colon cancer cells with low and high WNT 
activity were screened for consistently deregulated genes (Horst et al., 2012; 
Vermeulen et al., 2010). For analysis of colon cancer samples, microarray 
data produced on Affymetrix HG-U133Plus2.0 arrays were obtained from the 
Gene Expression Omnibus (GEO) and normalized with Robust Multi-array 
Average (RMA) using custom brainarray CDF (v19, ENTREZG) in R, which 
yielded one optimized probeset per gene, as previously described (Grünewald 
et al., 2016; Orth et al., 2015; Sahay et al., 2015). Samples used were 
GSE14333, GSE17536, and GSE39582. Pearson correlations of PBX3 
expression and expression of all other genes represented within these 
datasets were calculated, and genes were ranked accordingly. GSEA 
analyses then were done using this ranked gene list against curated sets of 
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EMT core signatures (Anastassiou et al., 2011; Taube et al., 2010). Heatmaps 
for selected genes were drawn with GENE-E (Broad Institute). 
 
4.10. Panel sequencing 
 
For next-generation panel sequencing, we used the Ion AmpliSeq Cancer 
Hotspot Panel v2, covering the mutational status of 50 oncogenes and tumor 
suppressor genes, according to the manufacturers protocol (Life 
Technologies). 31 days after recombination, individual clones from 
immunohistochemically stained slides of different SW1222 and HCT116 
xenograft tumors were microdissected and 1-5 ng DNA were used as 
template for library construction. Multiplexed libraries then were sequenced on 
an Ion Personal Genome Machine (Thermo Fisher). Reads were mapped to 
human reference genome hg19 and filtered for non-synonymous variants. 
 
 
4.11. Analysis of clone characteristics 
 
To determine clone sizes, we counted neighboring tumor cells with identical 
fluorescent colors on confocal images. For each clone, we then determined 
the positions of each cell C (xC, yC), as well as the closest positions of leading 
tumor edge E (xE, yE) and tumor necrosis N (xN, yN) using ImageJ (NIH). 
Using geometric shifting and rotation, we then transformed coordinates so 
that E’ (0, 0) and N’ (xN’, yN’) with xN’ = yN’. The resulting cell positions C’ (xC’, 
yC’) for each clone then were analyzed in Microsoft Excel for linear correlation 
by t test, the slope of the linear regression m was determined, and the angle θ 
of the line of best fit with the x-axis was calculated by θ = tan-1(m). The angle 
α of each clone relative to a tangent to the leading tumor edge then resulted 
from α = θ + 45°. 
 
 
4.12. Simulation Model  
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The two-dimensional spatial simulation model was implemented in VBA-Excel 
(Suppl. Excel Application). In a worksheet “Clones”, simulating 60x60 cells, 
random numbers from 1 to 3,600 were distributed. These are illustrated in a 
60x60 matrix in worksheet “Graphics” with ten different colors, determined by 
clone number modulo 10. For each simulation cycle for cells at the bottom 
row, representing the leading tumor edge, each cell content is either copied to 
neighboring cells on the left or right, simulating lateral expansion for clonal 
competition, or the cell above, simulating clonal outgrowth towards the tumor 
center, while this behavior is determined at random. For all remaining cells, 
contents are copied to the cell above, while this is restricted to every Nth row, 
with N simulating the proliferation gradient from leading tumor edge (bottom 
row) to tumor center (other rows). Contents of cells that are to be replaced are 
shifted to cells immediately above, causing loss of “clones” only at the top row 
of the model, which simulated tumor cells next to tumor necrosis. Frequencies 
are recorded in worksheet “Numbers” and represented in a diagram in 
worksheet “Graphics”. 
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5. Results 
 
5.1. Multicolor lineage tracing reveals structural organization and clonal 
dynamics in colon cancer 
 
The results presented in this section are part of the publication: Lamprecht S, 
Schmidt EM, Blaj C, Hermeking H, Jung A, Kirchner T, Horst D. Multicolor lineage 
tracing reveals clonal architecture and dynamics in colon cancer. Nature 
Communications 2017; 8: 1406. 
 
 
5.1.1. Differentiation gradients in colon cancer 
 
First we assessed primary colon cancers for the expression of nuclear β-catenin and 
FRA1 as surrogate markers for high WNT and MAPK signaling (Tetsu and 
McCormick, 1999; Vial et al., 2003) that were previously linked to tumor initiating 
potential and colon cancer stem cells. In addition we determined expression of 
CK20 and GLUT1 that in contrast indicated epithelial cell differentiation and hypoxia, 
respectively (Bristow and Hill, 2008; Vial et al., 2003). Many colon cancers showed 
increased nuclear β-catenin and FRA1 expression in tumor cells located at the 
infiltrative tumor edge, whereas CK20 and GLUT1 were most strongly expressed in 
the tumor center, often close to necrotic areas, suggesting strong differentiation 
gradients directed from the tumor edge towards the tumor center. However, a 
substantial number of colon cancers did not show definite intratumoral differentiation 
gradients, since they either expressed these markers more randomly throughout the 
tumor, or were negative for individual markers (Figures 9A and B). 
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Figure 9: Varying degrees of differentiation gradients in colon cancer. (A)  
Immunohistochemistry for indicated proteins in representative primary colon cancers used to classify 
organized and disorganized tumor growth based on presence or absence of strong differentiation 
gradients. All micrographs show tumors from leading tumor edge (image bottom) to tumor center or 
central tumor necrosis (image top).  Arrowheads indicate positively stained tumor cells. Scale bars 
100µm. (B) Frequencies of observed marker distributions in colon cancer (n=92). 
 
These findings suggested that colon cancers may be categorized into tumors with 
polarized or more diffuse expression of differentiation antigens and markers related 
to colon cancer stem cells (Figure 10).  
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Figure 10: Differentiation gradients in colon cancers. Schematic model for organized (left panel) 
and disorganized (right panel) colon cancers with and without differentiation gradients, respectively. 
 
Next, we characterized a collection of colon cancer xenografts and found that 
SW1222 derived tumors showed the same distribution of nuclear β-catenin, FRA1, 
CK20 and GLUT1 as primary colon cancer cases, while HCT116 colon cancer 
xenografts showed more diffuse marker expression and lack of differentiation 
gradients (Figure 11). We therefore used xenografts of these two cell lines as model 
tumors for the typical spectrum of presence or absence of differentiation gradients 
that is observed in primary colon cancers. 
 
 
Figure 11: Xenografts of colon cancer cell lines reflect primary colon cancer architecture. 
Immunohistochemistry for indicated proteins in SW1222 and HCT116 derived xenografts 
demonstrate presence or absence of strong differentiation gradients, respectively. All micrographs 
show tumors from leading tumor edge (image bottom) to tumor center or central tumor necrosis 
(image top). Arrowheads indicate positively stained tumor cells. Scale bars 100 µm. 
   Results 
 
40 
 
5.1.2. Multicolor lineage tracing of colon cancer cells in vivo 
 
In order to visualize lineage outgrowth in colon cancer, we developed a lentiviral Cre 
recombinase sensitive reporter system that allows stochastic expression of different 
fluorescent colors in individual tumor cells. Our system consists of three lentiviral 
vectors, two of which mediate doxycycline-inducible expression of an estrogen 
receptor-Cre fusion protein (pLenti rtTA3G and pLenti TetO-CreERT2). Upon Cre 
recombination the third vector randomly switches from expression of orange to 
either tagged red, yellow, or blue fluorescence proteins (pLenti Multicolor, Figure 
12). 
 
 
 
Figure 12: Lentiviral vectors for expression of rtTA (pLenti rtTA3G), doxycycline dependent 
CreERT2 (pLenti TetO-CreERT2), and the Cre-responsive multicolor transgene (pLenti 
Multicolor). Upon Cre-recombination, transgene elements flanked by loxN, lox2272, or loxP sites will 
be removed at random, causing an irreversible switch from expression of orange (OFP) to tagged red 
(RFP-FLAG), yellow (YFP-V5), or blue fluorescence (BFP-VSV), respectively. LTR, long terminal 
repeat; TRE, tetracycline response element; BlastR/PuroR, blasticidin and puromycin resistance 
genes. PRE posttranscriptional regulatory element. 
 
This doxycycline and tamoxifen controlled design was completely devoid of 
unwanted background recombination (data not shown). We then transduced all 
three vectors into SW1222 and HCT116 colon cancer cells, expanded single cell 
clones, and xenografted them into immune compromised NOD/SCID mice (Figure 
13A). After xenograft growth, we induced recombination by doxycycline and 
tamoxifen treatment and analyzed clonal outgrowth over time (Figure 13B). 
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Figure 13: Workflow for Xenograft experiments. (A) Triple transduced colon cancer cells were 
xenografted into NOD/SCID mice. (B) Schedule for doxycycline (DOX) and tamoxifen (TAM) 
treatment, and tumor harvest after xenografting 
 
Three days after induction of recombination, individual or small clusters of colon 
cancer cells were randomly labelled by different fluorescent colors in a mosaic 
pattern throughout SW1222 and HCT116 xenograft tumors. Of note, multiple vector 
integrations resulted in various combinatorial fluorescent colors (Figure 14). 
 
  
Figure 14: Mixed fluorescent color expression due to multiple vector insertions. (A) Upon 
insertions of e.g. three copies of pLenti Multicolor, by chance one, two or three inserted transgenes 
may recombine, resulting in up to 13 different single or mixed fluorescent colors. (B) Fluorescent 
color spectrum in an HCT116 xenograft tumor three days after recombination. Scale bar, 25 µm. 
 
Interestingly, at this early time point after recombination, we already observed loss 
of few color labelled clones into the central tumor necrosis (Figure 15). Ten days 
after recombination, single color clones had increased in size, while at 31 days after 
recombination, large stripe- and wedge-like shaped clones completely extended 
from the tumor edge to the necrotic tumor center (Figures 15 and 16). Inducible 
multicolor labeling thus allowed us to monitor clonal outgrowth within human colon 
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cancer in vivo, and suggested clonal expansion along axes from the tumor edge 
towards the tumor center.  
 
 
Figure 15: Stochastic clone formation in vivo. Confocal immune fluorescence for RFP-FLAG 
(red), YFP-V5 (green) and BFP-VSV (blue) in indicated xenografts (n ≥ 3) at indicated time points 
after tamoxifen induced multicolor labeling. Fluorescent images show xenograft tumors from leading 
tumor edge (image bottom) to central tumor necrosis (image top). Scale bars, 50 µm   
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Figure 16: Phenotypes of subclones in colon cancer xenografts. Immunohistochemistry for 
indicated tagged fluorescence proteins illustrates representative clonal patches in SW1222 and 
HCT116 xenograft tumors 31 days after recombination. Micrographs show tumors from leading tumor 
edge (image bottom) to tumor center or central tumor necrosis (image top). Scale bars, 100 µm. 
 
 
5.1.3. Clone characteristics in colon cancer 
 
To characterize the shape and architecture of colon cancer subclones in more 
detail, we determined the coordinates of coherent tumor cells with identical colors 
relative to perpendicular linear axes from the tumor edge to the necrotic tumor 
center (Figure 17A). An adapted model for linear regression analyses revealed that 
31 days after recombination most clones had expanded in a linear manner in 
SW1222 and HCT116 xenografts, while we observed this with less significance at 
earlier time points (Figure 17B). Moreover, when we determined the angles (α) of 
lines fitted to clones by linear regression, relative to tangents to the leading tumor 
edge (Figure 17A), these predominantly centered around 90° in tumors of both cell 
lines (Figure 17C).  
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Figure 17: Shape and axis formation of colon cancer subclones. (A) Schematic illustration of 
clonal analysis. Positions of cells in individual clones relative to leading tumor edge and central tumor 
necrosis were determined. For each clone, a line of best fit for cell positions then was calculated by 
linear regression, yielding a clonal axis. α indicates the angle of the clonal axis relative to the leading 
tumor edge. (B) Significance of linear alignment of cells in individual clones at indicated time points 
after multicolor labeling. (C) Angles (α) of clonal axes relative to the leading tumor edge at indicated 
time points after multicolor labeling   
 
In addition, we then performed BrdU tracing experiments and found that within six or 
seven days after a single BrdU pulse, the label progressed from the tumor edge 
toward the tumor center (Figure 18).  
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Figure 18: BrdU tracing in colon cancer xenografts. (A) Schema and experimental schedule. (B, 
C) Immunohistochemistry for BrdU in SW1222 and HCT116 xenograft tumors at indicated time points 
after BrdU pulse. Micrographs show tumors from leading tumor edge (image bottom) to tumor center 
or central tumor necrosis (image top). Scale bars, 100 µm in (B) and 50 µm in (C). (D, E) 
Quantification of average relative BrdU staining intensity from tumor edge to tumor center. Data are 
mean with 95 % confidence bands and derived from different xenograft areas (n ≥ 20) of independent 
biological replicates (n ≥ 3).   
 
Collectively, these findings provided evidence of a non-random linear expansion of 
tumor cell clones, perpendicular to the leading tumor edge and directed towards the 
tumor center. 
With these findings in mind, we analyzed the distribution of nuclear β-catenin, FRA1, 
CK20, and GLUT1 within individual clones. As expected for organized SW1222-
derived xenografts, nuclear β-catenin and FRA1 marked tumor cells predominantly 
at the leading tumor edge, while CK20 and GLUT1 marked cells close to the 
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necrotic tumor center within these clones, indicating clonal axis formation along the 
centripetal differentiation axis in these tumors (Figures 19 and 20). 
 
 
Figure 19: Marker distribution in CRC Xenografts. Confocal images show positions of indicated 
stem cell and differentiation antigens (red) in individual clones (green) of colon cancer xenografts. 
Fluorescent images show xenograft tumors from leading tumor edge (image bottom) to central tumor 
necrosis (image top). Scale bars, 50 µm. 
 
Importantly, however, since clonal axes in disorganized HCT116 colon cancer 
xenografts also were perpendicular to the leading tumor edge and all four markers 
were more randomly expressed in individual clones of these tumors, this indicated 
that clonal axis formation does not generally parallel or depend on differentiation 
gradients. These findings suggested limited influence of differentiation gradients on 
clonal architecture and outgrowth in colon cancer. (Figures 19 and 20). 
 
 
Figure 20: Differentiation gradients in colon cancers. Schematic model suggesting identical 
clonal outgrowth in organized and disorganized colon cancers with and without centripetal 
differentiation gradients, respectively. 
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5.1.4. Clonal dynamics in colon cancer 
 
To further learn about clonal dynamics in colon cancer xenografts, we analyzed 
clone sizes and clonal density after multicolor labeling over time. Three days after 
recombination, clones were composed of two-three cells in average. Clone sizes 
then increased exponentially until 17 days with subsequently slightly slowed growth 
rates (Figure 21). Accordingly, clonal density, i.e. the number of clones per area, 
decreased over time. Importantly, when comparing clonal density at the tumor edge 
and close to the central tumor necrosis, we observed a significantly earlier decrease 
in clonal density at the leading tumor edge, most obvious at 10 days and 17 days 
after recombination in both SW1222 and HCT116 colon cancer xenografts (Figure 
21). 
 
 
Figure 21: Clonal analysis in vitro over time. Clone sizes (left panels) and clones per area (right 
panels), as determined by analysis of confocal fluorescence images of SW1222 and HCT116 colon 
cancer xenografts at different time points after multicolor labeling. Clones per area were measured 
overall and separately in tumor thirds close to the tumor edge and close to central tumor necrosis, as 
indicated. *** P < 0.001 and ** P < 0.01 indicate differences between tumor edge and tumor center by 
t-test. 
 
Also, over time the average clonal width at the leading tumor edge linearly increased 
when adjusted to increases in tumor circumference (Figure 22). 
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Figure 22: Lateral clonal expansion in colon cancer xenografts. Measurements of clonal width at 
the leading tumor edge divided by relative changes in tumor circumference (Adjusted clonal width) 
are shown for indicated time points after multicolor recombination. a.u, arbitrary units. Error bars 
indicate mean ± SD. **, P < 0.01; ***, P < 0.001; n.s., nonsignificant by t test.  
 
Together with the observation that clones could be lost into central tumor necrosis, 
these findings suggested that clonal competition mainly occurred at the leading 
tumor edge with subsequent clonal outgrowth towards the necrotic tumor center. Of 
note, when we analyzed individual clones 31 days after recombination for cancer hot 
spot mutations, no mutational differences were observed. This indicated that clonal 
outgrowth and competition likely occured in the absence of overt changes in driver 
mutation profiles (Table 1). 
 
Table 1: Mutational status of individual microdissected subclones of SW1222 and HCT116 xenograft 
tumors, 31 days after recombination 
 
                                       SW1222 clones                          HCT116 clones                                      
Gene    Mutation #1 #2 #3 #4 #5  #1 #2 #3 #4 #5 
KRAS G13D x x x x x       
CTNNB1 S45 del x x x x x       
PIK3CA H1047R x x x x x       
SMO V404M x x x x x       
ABL1 D276G x x x x x       
KRAS A146V       x x x x x 
APC G1306T       x x x x x 
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Finally, we inferred a two-dimensional spatial simulation model for clonal dynamics 
in colon cancer, implementing few rules only that we derived from our in vivo 
observations (Figure 23).  
 
 
Figure 23: Two-dimensional simulation model for clonal outgrowth. Bottom row simulates tumor 
cells at the tumor edge and top row simulates tumor cells neighboring tumor necrosis. At the tumor 
edge cells divide during each simulated replication cycle and probabilities for cell expansion upwards 
P(U), to the left P(L) or to the right P(R) are equal. In other positions, cells divide upwards only at 
decreased frequency with P(U) = 0.5. Panels simulate one possible outcome for four replication 
cycles. 
 
First, clones may only be lost into the tumor center or into central tumor necrosis, 
represented by the upper border of our square model. Second, clonal competition by 
lateral clone expansion may only occur at the leading tumor edge, represented by 
the lower border of the model. Third, based on measurements of proliferation by 
Ki67 in primary colon cancers (n=92) and xenograft tumors (Figure 24), growth rates 
in our model were slowed to 0.5 in central tumor areas relative to the leading tumor 
edge.  
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Figure 24: Proliferation gradients in colon cancer. (A) Representative immunohistochemistry and 
(B) quantification of Ki67 in primary colon cancers (n = 92) and in SW1222 and HCT116 xenograft 
tumors (4 different areas in 3 biological replicates), as indicated. Micrographs show tumors from 
leading tumor edge (image bottom) to tumor center or central tumor necrosis (image top). Scale bars, 
100 µm. Error bars indicate mean ± SD. P values are t test results. 
 
This model, when composed of few “cells” only, illustrated rapid loss of individual 
tumor cells and a drift towards mono-clonality (Figure 25). 
 
 
Figure 25: Two-dimensional simulation model for clonal outgrowth. Bottom row simulates tumor 
cells at the tumor edge and top row simulates tumor cells neighboring tumor necrosis. At the tumor 
edge cells divide during each simulated replication cycle and probabilities for cell expansion upwards 
P(U), to the left P(L) or to the right P(R) are equal. In other positions, cells divide upwards at 
decreased frequency with P(U) = 0.5. One possible outcome after 30 replication cycles is illustrated. 
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In larger scale, linear expansion of tumor cell clones from the leading tumor edge 
towards the central tumor necrosis were seen with widening of some clones and 
inevitable loss of those that lost contact to the leading edge, causing a continuous 
drift towards oligo-clonality, well-fitting our in vivo findings (Figure 25). 
 
Also, the dynamics of gains in clone size and loss in clone density over time 
quantitatively matched our observations in colon cancer xenografts (Figure 26). 
 
 
Figure 26: Clonal analysis within the simulation model. Average clone sizes (left panel) and 
clones per area (right panel) from 100 independent simulations. Clones per area (arbitrary units) are 
given overall, and in thirds of the model close to tumor edge and central tumor necrotic core, 
respectively. Dotted lines approximately deliminate simulation segments fitting our in vivo data. 
 
Importantly, this also included an earlier decrease of clonal density at the leading 
tumor edge compared to the tumor center, which was due to the implemented 
restriction of clonal competition to the leading tumor edge. Collectively, this model 
corroborated the idea that the in vivo observed clonal outgrowth from the leading 
tumor edge towards the tumor center may be based on few rather positional 
characteristics of colon cancer cells while differentiation gradients may be of less 
importance.  
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5.2. Identification of PBX3 as an inducer of EMT signaling in colon 
cancer 	
 
The results presented in this section are part of the publication: Lamprecht S, Kaller 
M, Schmidt EM, Blaj C, Hermeking H, Grünewald T G, Jung A, Kirchner T, Horst D. 
PBX3 is part of an EMT regulatory network in colorectal cancer and indicates poor 
outcome. Clin Cancer Res. 2018; 24(8):1974-1986  
 
 
5.2.1. PBX3 is overexpressed in colon cancer cells with high WNT activity 
 
To find transcription factors linked to WNT signaling activity in colon cancer, we 
screened three previously published gene expression data sets that were derived 
from colon cancer cell subpopulations with low and high WNT activity (Horst et al., 
2012; Vermeulen et al., 2010). Of 956 represented genes that encoded for known or 
putative transcription factors, 69 (7.2 %) were significantly (P < 0.05 by t-test) 
differentially expressed by 1.5 fold or more. Among those with most consistent 
overexpression in tumor cells with high WNT activity that expectedly included known 
WNT pathway components or target genes such as LEF1, PROX1, and ZEB1, we 
identified PBX3 (Figure 27, Table 2). 
 
 
Figure 27: Volcano plot of protein expression. Volcano plot of gene expression data of genes 
encoding for transcription factors, derived from three pooled data sets comparing colon cancer cells 
with high and low WNT activity. Colored dots denote genes that in each data set are significantly (P < 
0.05) upregulated (red) or downregulated (blue).  
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Table 2: Differentially expressed genes (F.C.≥1.5; P≤0.05) encoding for known or putative 
transcription factors derived from three gene expression data sets of colon cancer cells with high vs. 
low WNT activity. P values are t test results.  
 
Gene Symbol F.C. WNT high vs. low P value WNT high vs. low 
PROX1 5.64 0.0002 
ZEB1 3.48 0.0011 
LEF1 3.31 0.0064 
DLX5 3.3 0.0443 
TCF4 3.01 0.0106 
HOXD9 2.84 0.0124 
IRX5 2.74 0.003 
NFE2 2.45 0.0053 
ETV1 2.38 0.0105 
ELF5 2.33 0.0389 
SNAI2 2.28 0.0363 
NKX2-1 2.21 0.0176 
HEY2 2.19 0.0327 
MEIS1 2.16 0.0005 
SIX2 2.1 0.0494 
HNF1B 1.99 0.0079 
GBX2 1.97 0.0179 
ZIC4 1.94 0.0248 
PHOX2B 1.88 0.0467 
TBX10 1.83 0.0046 
ETV5 1.81 0.0017 
EGR3 1.8 0.006 
TEF 1.8 0.0242 
EGR4 1.79 0.0272 
KLF9 1.77 0.0002 
ZNF467 1.77 0.0359 
SMARCA1 1.75 0.0087 
ZBTB7B 1.7 0.0133 
ZNF287 1.69 0.04 
PBX3 1.68 0.0007 
ZFP30 1.65 0.0125 
ZFP2 1.63 0.0427 
NFATC1 1.62 0.01 
ELK3 1.62 0.0005 
ZNF236 1.61 0.0064 
KLF12 1.6 0.0001 
NKX3-1 1.6 0.0087 
ZBTB1 1.6 0.008 
ZBTB20 1.58 0.0076 
ZBTB44 1.55 0.0086 
PAX8 1.54 0.0335 
DNMT3B 1.54 0.0183 
MIER2 0.66 0.0296 
NFKBIL1 0.63 0.0192 
RARB 0.62 0.0269 
FLI1 0.6 0.0485 
FOXE1 0.59 0.0431 
SIX5 0.59 0.0414 
NR3C2 0.57 0.0014 
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Gene Symbol F.C. WNT high vs. low P value WNT high vs. low 
ZNF154 0.55 0.0484 
HOXB1 0.55 0.0254 
BHLHE41 0.55 0.0001 
NR1H4 0.53 0.0085 
MYT1 0.5 0.0073 
MEF2C 0.5 0.0337 
SOX17 0.49 0.0178 
TFEC 0.48 0.0094 
CREB3L1 0.48 0.0049 
ESR1 0.47 0.0109 
NKX6-1 0.47 0.0089 
GATA4 0.45 0.0347 
NEUROG1 0.45 0.0108 
FEV 0.44 0.0471 
MAF 0.43 0.0307 
ZXDB 0.42 0.0424 
SPDEF 0.39 0.0377 
FOXG1 0.36 0.03 
MEOX2 0.34 0.0251 
 
 
Indeed, in this data set increased PBX3 expression coincided with high expression 
of WNT pathway components and target genes and, conversely, with repression of 
genes associated with a differentiated tumor cell phenotype (Figure 28). 
 
 
 
 
Figure 28: PBX3 is overexpressed in colon 
cancer cells with high WNT activity. 
Heatmaps of PBX3, selected WNT targets, and 
differentiation factors in three data sets (D1–
D3) of colon cancer cells with high and low 
WNT activity. 
 
 
 
 
We then examined tissues sections of individual colon cancers and found that PBX3 
was heterogeneously expressed with strongest expression at the leading tumor 
edge, where it overlapped with strong expression of nuclear β-catenin, indicating 
high WNT activity. These findings identified upregulation of PBX3 in colorectal 
cancer cells with high WNT activity on mRNA and protein levels, and suggested a 
possible regulation of PBX3 by WNT (Figure 29). 
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Figure 29: Correlation of PBX3 and β-catenin. (A) Immunohistochemical staining of serial sections 
illustrate upregulation of PBX3 in areas with increased β-catenin staining (arrows). scale bar, 50 µm. 
(B) Quantification of immunohistochemical signals for PBX3 and β-catenin. Values are given as 
staining intensity for individual tumor cells (n ≥ 300) of different colorectal cancer samples (n ≥ 6). P 
values are results of linear regression analyses.     
 
 
5.2.2. PBX3 expression is regulated by WNT signaling in colorectal cancer 
 
Next, we determined whether PBX3 expression depended on high WNT activity in 
colon cancer. Reducing WNT activity by depletion of β-catenin with two different 
siRNAs reduced PBX3 in different colon cancer cell lines on the protein level, 
whereas transfection with control siRNA had no effect on PBX3 (Figure 30).  
 
Figure 30: β-catenin knockdown reduced PBX3 expression. Immunoblotting of indicated proteins 
after transfection of different colon cancer cells with siRNA against β-catenin. Numbers below 
immunoblots indicate fold change by densitometry. 
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We confirmed these effects on the mRNA level by qRT-PCR in two cell lines, in 
which β-catenin knockdown significantly downregulated PBX3 expression and that 
of the WNT target genes AXIN2, NKD1 and LGR5 (Figure 31) (Barker et al., 2007; 
Yan et al., 2001). 
 
 
Figure 31: β-catenin knockdown represses PBX3 expression. qRT-PCR results on indicated 
genes after knockdown of β-catenin. Error bars indicate mean ± SD. **, P < 0.01; ***, P < 0.001 by t 
test, n ≥ 3. 
 
Furthermore, we tested the effects of a doxycycline (DOX) inducible dominant 
negative TCF4 (dnTCF4), a potent inhibitor of the β-catenin/TCF4 transcription 
factor complex (Van de Wetering et al., 2002). In two cell lines, dnTCF4 induction 
strongly reduced transcription from β-catenin/TCF4 binding sites, as seen in 
TOPflash luciferase reporter assays (Figure 32, left panel) but also decreased PBX3 
protein expression and downregulated PBX3 mRNA levels among the panel of WNT 
target genes (Figure 32, middle and left panel).  
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Figure 32: Effects of WNT pathway inhibition on PBX3. Immunoblotting (A), Dual-luciferase 
assays with TOPflash reporter constructs (B) and qRT-PCR (C) results on indicated proteins or 
genes after inhibition of the β-catenin/TCF4 by doxycycline dependent induction dnTCF4 in HEK293 
cells. Error bars indicate mean ± SD. *, P < 0.05; **, P < 0.01; ***, P < 0.001 by t test, n ≥ 3. 
 
On the contrary, stimulation of HEK293T, a cell line with low intrinsic WNT activity, 
with WNT3a led to strong overexpression of PBX3 and active β-catenin on the 
protein level, as well as upregulation of PBX3 and WNT target gene mRNA (Figure 
33).  
 
 
Figure 33: Effects of WNT pathway activation on PBX3. Immunoblotting (A) and qRT-PCR (B) 
results on indicated proteins or genes after stimulation of HEK293 cells with WNT3a. Numbers below 
immunoblots indicate fold change by densitometry. Error bars indicate mean ± SD. *, P < 0.05; **, P < 
0.01; ***, P < 0.001; n.s., not significant by t test , n ≥ 3. 
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Taken together these findings suggested that PBX3 expression is regulated by WNT 
signaling in colon cancer, while this effect is not cell type specific. 
To test for direct transcriptional regulation of PBX3 by WNT, we then screened the 
PBX3 promoter sequence and identified three putative β-catenin/TCF4 binding 
motifs (WWCAAAG (Korinek et al., 1998)) within 2.5 kb 5’ of the first exon of the 
PBX3 gene (Figure 34). 
 
 
Figure 34: TCF4 binding motifs within the PBX3 promoter sequence. three putative β-
catenin/TCF4 binding motifs were found within within 2.5 kb of the PBX3 promoter sequence.  
 
To determine if PBX3 is induced by WNT activation via these β-catenin/TCF4 motifs, 
we subjected 2.5 kb of the PBX3 promoter region including these motifs, or mutated 
motifs as control, to dual luciferase reporter assays. Unexpectedly, WNT3a 
stimulation did not increase luciferase expression from the wild-type reporter (Figure 
35, A), while TOPflash assays confirmed strong transcriptional activation of WNT 
signaling by WNT3a (Figure 35, B). These data suggested that PBX3 is no direct β-
catenin/TCF4 target gene but instead modulated by other WNT dependent 
downstream factors. 
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Figure 35: No effects of WNT activation on β-catenin/TCF4 motifs within the PBX3 promoter. 
Dual-luciferase assays with wildtype or mutated reporter constructs of the PBX3 promoter (A) and 
TOPflash reporter constructs (B) after stimulation of HEK293 cells with WNT3a. Error bars indicate 
mean ± SD. ***, P < 0.001; n.s., not significant by t test, n ≥ 3.  
 
 
5.2.3. PBX3 is strongly associated with EMT in colon cancer 
 
Since PBX3 expression was strongest in tumor cells located at the infiltrative tumor 
edge with high WNT activity (Figure 29), and WNT signaling is a known regulator of 
EMT in colon cancer (Brabletz et al., 2005), we hypothesized that PBX3 might be 
linked to EMT. To test for a general association of PBX3 with an EMT phenotype, 
we assembled and normalized publicly available mRNA expression data of 1.097 
colon cancers. Supporting our hypothesis, Gene Set Enrichment Analyses (GSEA) 
conceded highly significant (p<0.001) overlap of PBX3 expression and the 
expression of two published core EMT gene signatures (Figure 36) (Anastassiou et 
al., 2011; Taube et al., 2010). 
 
 
Figure 36: PBX3 correlates with a mesenchymal 
transition signature. GSEA for genes ranked by Pearson 
correlation (Pearson r) to PBX3 expression for two EMT 
target gene signatures by Anastassiou and colleagues 
(orange curve: ES = 0.89, P < 0.001) and Taube and 
colleagues (green curve: NES = 0.84, P = 0.001) in 1.097 
RNA-Seq datasets of colon cancer from TCGA. 
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Additionally, factors that reportedly imply EMT activity in CRC were upregulated in 
tumors that showed high levels of PBX3 expression, among them most prominently 
ZEB1 (r=0.69, p<0.0001), a known inducer of EMT in colon cancer cells (Figure 37). 
 
 
 
 
 
Figure 37: PBX3 is overexpressed in colon 
cancers with high expression of EMT related 
genes. Heatmaps of PBX3, selected mesenchymal 
and epithelial targets in a dataset of 1.097 colon 
cancers. Colors represent Pearson r from -1 (blue) to 
1 (red). 
 
 
 
On the contrary, CDH1, the epithelial differentiation marker negatively correlated 
with PBX3, further supporting the idea of an association of PBX3 and EMT. To shed 
more light on PBX3 and EMT in situ, we subsequently assessed colon cancer 
tissues for PBX3 and LAMC2, a factor regulated by ZEB1 (Sanchez-Tillo et al., 
2011) by immunohistochemistry, and found a highly significant correlation of both 
markers (Figure 38). Taken together these data demonstrated that PBX3 is 
associated with an EMT tumor cell phenotype in colon cancer (Peinado et al., 2007; 
Sánchez-Tilló et al., 2012). 
 
Figure 38: Correlation of PBX3 and LAMC2. (A) Immunohistochemical staining of serial sections 
illustrate upregulation of PBX3 in areas with increased LAMC2 staining (arrows). scale bar, 50 µm. 
(B) Quantification of immunohistochemical signals for PBX3 and LAMC2. Values are given as 
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staining intensity for individual tumor cells (n ≥ 500) of different colorectal cancer samples (n ≥ 5). P 
values are results of linear regression analyses 
5.2.4. PBX3 is induced by EMT in colon cancer and required for a full EMT 
phenotype 
 
EMT can be induced in colon cancer cells by ectopic expression of SNAIL or ZEB1 
(Peinado et al., 2007), and we applied this approach to test if PBX3 expression is 
EMT dependent. We used a DOX inducible episomal vector system to overexpress 
either SNAIL or ZEB1 in DLD-1 and LS174T cells, two colon cancer cell lines with 
low EMT marker expression and pronounced epithelial phenotypes (Jackstadt et al., 
2014). In both cell lines, induction of SNAIL by DOX treatment caused upregulation 
of PBX3 protein levels within 12 h and also increased PBX3 mRNA levels together 
with VIM and ZEB1, while repressing CDH1 and miR-200c, indicating an EMT 
phenotype (Figure 39).  
 
 
Figure 39: SNAIL induces PBX3 expression. (A) Western blot analysis of PBX3 protein levels in 
LS174T and DLD-1 cells with a pRTR-SNAIL-VSV vector after treatment with DOX for the respective 
periods. Numbers below immunoblots indicate fold change by densitometry. (B) Gene expression 
analyses by qRT-PCR for indicated genes after 72 h DOX induction. Error bars represent mean ± 
SD. *, P < 0.05; **, P < 0.01; ***, P < 0.001 by t test, n ≥ 3.  
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Immune fluorescence further confirmed upregulation of PBX3 together with 
rearranged F-actin stress fibers, a characteristic feature of the EMT process (Figure 
40) (Moreno-Bueno et al., 2009). 
 
Figure 40: Clonal analysis within the simulation model. Representative confocal 
immunofluorescence images of LS174T and DLD-1 cells with a pRTR-SNAIL vector after treatment 
with DOX for respective proteins and DAPI as nuclear counterstain. Scale bars, 50 µm. 
 
Similarly, ZEB1 induction also caused upregulation of PBX3 protein and mRNA 
levels with downregulation of miR-200c in both cell lines, and CDH1 repression in 
DLD-1 cells, while it had less effect on the other EMT markers (Figure 41). 
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Figure 41: ZEB1 induces PBX3 expression. (A) Western blot analysis of PBX3 protein levels in 
LS174T and DLD-1 cells with a pRTR-ZEB1-VSV vector after induction with DOX for the respective 
periods. Numbers below immunoblots indicate fold change by densitometry. (B) PBX3 mRNA levels 
in the same experiment analogous to (A). Numbers below immunoblots indicate fold change by 
densitometry. Error bars represent mean ± SD. *, P < 0.05; **, P < 0.01; ***, P < 0.001 by t test, n ≥ 3. 
Because this suggested a regulation of PBX3 through the SNAIL-ZEB signaling axis 
(Thiery et al., 2009), we next examined the effects of ZEB1 depletion on PBX3 in 
SW480 and Colo320 colon cancer cells, both of which have high levels of ZEB1 and 
a mesenchymal phenotype, when compared to DLD-1 and LS174T (Hahn et al., 
2013). Indeed, ZEB1 depletion by siRNA decreased PBX3 protein and mRNA while 
miR-200c significantly increased in both cell lines (Figure 42). PBX3 therefore not 
only correlates with a mesenchymal phenotype but also is induced by EMT in colon 
cancer, while this appears to depend on ZEB1. 
 
 
Figure 42: ZEB1 knockdown represses PBX3 expression. (A) Immunoblotting of indicated 
proteins after transfection of SW480 and LOVO colon cancer cells with siRNA against ZEB1. 
Numbers below immunoblots indicate fold change by densitometry. (B) PBX3 mRNA levels in the 
same experiment analogous to (A). Error bars represent mean ± SD. *, P < 0.05; **, P < 0.01; ***, P < 
0.001 by t test, n ≥ 3. 
 
Because EMT induction by ZEB1 causes repression of miR-200, and PBX3 is a 
recently identified miR-200 target, we asked whether the effects of ZEB1 on PBX3 
may be indirectly mediated through this miRNA. Using TargetScan (Lewis et al., 
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2005), we found that a 7-mer seed-matching sequence of miR-200b/c within in the 
PBX3 3’UTR was highly conserved across several species (Figure 43). 
 
 
Figure 43: Putative miR-200c binding sites within the PBX3 3’UTR. Illustration of the miR-200c 
seeds and seed-matching sequences in the 3´-UTR of PBX3 (modified from www.targetscan.org).  
 
Transfection of SW480 and Colo320 colon cancer cells with miR-200c repressed 
both ZEB1 and PBX3, with stronger effects on protein than on mRNA levels, as 
expected for direct miRNA effects (Figure 44). 
 
 
Figure 44: miR-200c represses PBX3 expression. (A) Western blot analysis of PBX3 protein levels 
in SW480 and Colo320 cells 48 hours after transfection with miR-200c or miR control. Numbers 
below immunoblots indicate fold change by densitometry. (B) PBX3 mRNA levels in the same 
experiment analogous to (A). Error bars indicate mean ± SD. *, P < 0.05; **, P < 0.01; ***, P < 0.001 
by t test, n ≥ 3. 
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We then cloned the 3’UTR of PBX3, including the miR-200 seed-matching 
sequence, 3’ of a luciferase open reading frame (Figure 45), and found significant 
down-regulation of the reporter activity upon transfection with miR-200c (Figure 46), 
or upon siRNA mediated knockdown of ZEB1 (Figure 47).  
 
Figure 45: Mutation of the PBX3 3´-UTR. miR-200c seed and miR-200c seed-matching sequence 
shown with the remaining matches (black bars; WT: wild-type, MUT: mutated) 
 
 
Figure 46: miR-200c represses the PBX3 reporter activity. Analysis of the luciferase reporter 
activity in SW480 and Colo320. Cells were transfected 72 hours with pre-miR-200c or control 
oligonucleotides and the empty pGL3 vector or pGL3 with the indicated 3´-UTR-reporter constructs. 
Error bars indicate mean ± SD. **, P < 0.01;  ***, P < 0.001; n.s., not significant by t test, n ≥ 3. 
 
Both effects were abolished when using a luciferase reporter containing the 3’UTR 
of PBX3 with a mutated seed-matching sequence (Figures 46 and 47). These 
findings demonstrated that PBX3 is targeted by miR-200c, and suggested that ZEB1 
mediated induction of PBX3 occurs indirectly through de-repression of miR-200c. 
 
 
Figure 47: ZEB1 represses PBX3 reporter activity. Analysis of the luciferase reporter activity in 
SW480 and Colo320. Cells were transfected 72 hours with siRNA against ZEB1 or control 
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oligonucleotides and the empty pGL3 vector or pGL3 with the indicated 3´-UTR-reporter constructs. 
Error bars indicate mean ± SD., ***, P < 0.001; n.s., not significant by t test, n ≥ 3. 
 
To further determine if EMT in colon cancer also depended on PBX3 expression, we 
induced EMT by SNAIL in DLD-1 and LS174T cells and concomitantly depleted 
PBX3 by siRNA. While SNAIL expression caused downregulation of E-Cadherin, 
indicating loss of epithelial features, depletion of PBX3 partially reversed this effect 
(Figure 48). 
 
 
Figure 48: PBX3 affects EMT signaling. Immunoblotting of indicated proteins after transfection of 
SW480 and LOVO colon cancer cells with siRNA against PBX3 for 72 hours. Numbers below 
immunoblots indicate fold change by densitometry. 
 
Moreover, depleting PBX3 in SW480 and LoVo cell lines caused upregulation of E-
cadherin expression (Figure 49). These data implied that PBX3 expression is 
required for a full EMT phenotype in colon cancer cells. 
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Figure 49: Knockdown of PBX3 inhibited the SNAIL dependent reduction of E-cadherin. 
Western blot analysis in DLD-1 and LS174T cells with the pRTR-SNAIL vector for the respective 
proteins. Cells were transfected for 48 hours with the indicated siRNAs and further stimulated with 
either DOX or left untreated for further 36 hours. Numbers below immunoblots indicate fold change 
by densitometry. 
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5.2.5. High PBX3 expression is a strong indicator of colon cancer progression 
 
Due to its dependence on WNT signaling and EMT, both drivers of colon cancer 
progression, we examined the clinical significance of PBX3 expression in a 
collection of 244 colorectal cancer cases, all of which were stage II with clinical 
follow-up records (Table 3).  
 
Table 3: Clinical data and PBX3 expression in UICC stage II colorectal cancer.  
 
Characteristics Total 
  
PBX3 expression   P 
    negative   positive     
All patients 244 (100) 54 (22.1)   190 (77.9)     
Age (y, median 69.3)             
     ≤ 69 122 (100.0) 19 (15.6)   103 (84.4)   0.014 
     ≥ 70 122 (100.0) 35 (28.7)   87 (71.3)     
Gender             
     Male 131 (100.0) 27 (20.6)   104 (79.4)   0.54 
     Female 113 (100.0) 27 (23.9)   86 (76.1)     
T-stage (UICC)             
     T3 201 (100.0) 41 (20.4)   160 (79.6)   0.16 
     T4 43 (100.0) 13 (30.2)   30 (69.8)     
Tumor grade (WHO)             
     low 146 (100.0) 29 (19.9)   117 (80.1)   0.3 
     high 98 (100.0) 25 (25.5)   73 (74.5)     
 
Row percent values are given in parentheses           
 
While 72 tumors (30%) showed absence of PBX3 expression (score 0), 160 tumors 
(66%) had moderate levels (scores 1-2), and only 12 tumors (5%) high levels of 
PBX3 (score 3, Figure 50).  
 
 
Figure 50: PBX3 expression in colorectal cancer indicates poor prognosis. Assessment of 
PBX3 immunostaining in primary human colorectal cancers. Tumors were selected semiquantitative 
expression scores from 0 (no staining) to 3 (strong staining) and accordingly categorized as PBX3 
negative (score 0) and positive (scores 1-3). Arrows indicate stained tumor cells. Scale bar, 100 µm. 
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Kaplan-Meier statistics indicated significantly worse cancer specific patient survival 
when tumors expressed PBX3 (scores 1-3), when compared to lack of PBX3 
expression (score 0). Importantly, when choosing tumor progression as endpoint, 
we found an even stronger correlation of PBX3 expression and poor prognosis 
(Figure 51). Both findings were independent from other clinical variables in 
proportional hazards regression analyses (Tables 4 and 5). 
 
 
Figure 51: Loss of PBX3 expression reveals poor prognosis in CRC. Kaplan-Meier plots for 
different PBX3 expression scores and categories (lower panel) in a collection of n=244 stage II 
colorectal cancers. 
 
Table 4: Multivariate analysis of cancer specific survival in UICC stage II colorectal cancer. 
 
Variables Cancer specific survival  
  HR (95% confidence interval) P 
Age (≥ vs < median) 1.8 (1.02-3.09) 0.042 
Gender (F vs M) 0.8 (0.45-1.35) 0.367 
T-stage 2.5 (1.38-4.58) 0.003 
Tumor grade 2.2 (1.15-4.07) 0.017 
PBX3 positive vs negative 3.2 (1.35-7.61) 0.008 
 
Table 5: Multivariate analysis of disease free survival in UICC stage II colorectal cancer. 
 
Variables Cancer specific survival  
  HR (95% confidence interval) P 
Age (≥ vs < median) 1.1 (0.67-1.67) 0.816 
Gender (F vs M) 0.8 (0.51-1.28) 0.366 
T-stage 2.6 (1.58-4.29) 0.00017 
Tumor grade 2.0 (1.20-3.40) 0.008 
PBX3 positive vs negative 3.0 (1.50-6.14) 0.002 
 
Since tumor outcome of colon cancer mainly depends on distant metastasis, we 
further investigated PBX3 expression in a second, independent matched case-
control collection of 45 pairs of colon cancers with and without synchronous liver 
metastasis. In this collection, positive PBX3 expression (scores 1-3) were 
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significantly associated with liver metastasis (p=0.01, OR=3.0), further strengthening 
the link of PBX3 and poor prognosis (Table 6). 
 
Table 6: Clinical data and PBX3 expression in a case-control collection of colon cancers with and 
without distant metastasis. 
 
Characteristics Total 
  
PBX3 expression   P 
    negative   positive     
All patients 90 (100) 42 (46.7)   48 (53.3)     
Age (y, Median 68)             
     ≤ 68 47 (52.2) 20 (42.6)   27 (57.4)   0.41 
     ≥ 69 43 (47.8) 22 (51.2)   21 (48.8)     
Gender             
     Male 44 (48.9) 18 (40.9)   26 (59.1)   0.28 
     Female 46 (51.1) 24 (52.2)   22 (47.8)     
T-stage (UICC)             
     T2 8 (8.9) 2 (25)   6 (75   0.43  
     T3 66 (73.3) 32 (48.5)   34 (51.5)     
     T4 16 (17.8) 8 (50)   8 (50)     
Nodal status             
     N0 38 (42.2) 19 (50)   19 (50)   0.58 
     N+ 52 (57.8) 23 (44.2)   29 (55.8)     
Metastasis (Liver)             
     M0 45 (50) 27 (60)   18 (40)   0.011 
     M1 45 (50) 15 (33.3)   30 (66.7)     
Tumor grade (WHO)             
     Low 30 (33.3) 8 (26.7)   22 (73.3)   0.007 
     High 60 (66.7) 34 (56.7)   26 (43.3)     
              
Row percent values are given in parentheses           
 
Finally, for independent validation of these results, we analyzed clinical 
correlations of PBX3 mRNA levels with the assembled gene expression data 
set of 1,032 colon cancer cases, 927 of which had follow-up data on tumor 
progression. Using ROC curve analyses, we identified an ideal cutoff at the 
normalized expression intensity of 277 (natural scale) of PBX3 mRNA. 
Dichotomal classification of cases by this score revealed a highly significant 
positive correlation of high PBX3 expression and tumor progression in this 
data set (Figure 52). Collectively, PBX3 is a strong prognostic marker for 
tumor progression and poor survival in patients with colorectal cancer. 
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Figure 52: PBX3 expression in colorectal cancer indicates poor prognosis. PBX3 mRNA 
expression and survival association in individual and combined data sets of a total of n=927 
colon cancers. GEO accession numbers of individual data sets are indicated. Kaplan-Meier 
plots for cases with low and high PBX3 expression. P values are log-rank test results.
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6. Discussion 
 
6.1. Multicolor lineage tracing reveals clonal architecture and 
dynamics in colon cancer 
 
In this study, we implemented a quantitative lineage tracing strategy to gain 
unbiased insights into the clonal expansion dynamics of individual tumor cells 
within growing colon cancer in vivo. We used cell line derived colon cancer 
xenografts as model tumors to reproduce the architecture, cellular 
composition, and differentiation of primary human colon cancers (Cernat et 
al., 2014). Our data illustrate that colon cancer cells at the leading tumor edge 
compete for clonal outgrowth which is directed towards the tumor necrotic 
core. Although most  colon  cancers show central necrosis, this probably is 
not due to a commitment of colon cancer cells to die  but  rather  caused  by  
insufficient  nutrient  supply  in  the  center  of  rapidly  growing  tumors. 
In tumors with organized differentiation gradients this clonal expansion may 
coincide with tumor cell differentiation. These findings are in agreement with 
recent data demonstrating clonal outgrowth from tumor cells with high MAPK 
pathway activity or high expression of the WNT target gene LGR5 at the 
leading tumor edge (Blaj et al., 2017; Shimokawa et al., 2017). In this case, 
linear expansion of tumor cell subclones may be well compatible with lineage 
outgrowth from phenotypically defined colon cancer stem cells (Clevers, 
2011). Despite a distorted architecture, clonal outgrowth and differentiation in 
colon cancer therefore can be reminiscent of normal colonic mucosa, where 
stem cells at the crypt base compete for clonal repopulation of individual 
crypts (Chan et al., 2009; Snippert et al., 2010). Linear expansion of colon 
cancer subclones may thus be well compatible with lineages of a cancer stem 
cell model (Reya et al., 2001). 
However, colon cancer xenografts lacking differentiation gradients, and thus 
more disorganized growth, unexpectedly showed the same pattern of clonal 
expansion from tumor edge to center. Therefore, clonal fitness and positive 
clonal selection rather appear to depend on positioning of tumor cells at the 
leading tumor edge than on tumor cell differentiation. Indeed, when 
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considering widespread expression of putative cancer stem cell antigens in 
colon cancers (Horst et al., 2012), it may be difficult to imagine how a putative 
cancer stem cell that is trapped centrally within the tumor mass should 
efficiently compete for space and resources required for clonal expansion 
(Greaves and Maley, 2012). Based on our data, and supported by the results 
of our spatial computer model, which implemented positon as the only factor 
determining tumor cell behavior, we therefore propose that competition of 
colon cancer cells for clonal expansion is mainly restricted to the leading 
tumor edge. The phenotype of tumor cells within expanding clones may still 
be variable, depend on the individual genetic background of the tumor, and 
may secondarily be influenced by a position-related tumor microenvironment 
(Brabletz et al., 2001). 
Previous attempts to follow individually labelled tumor cells over time, 
independently of their phenotype, either used murine models, or lentiviral 
color- or bar-coding methods for random genetic labeling of tumor cells in vitro 
before xenotransplantation into mice (Cornils et al. 2014; Dieter et al. 2011; 
Weber et al. 2011; Zomer et al. 2013). While the approach in murine models 
is not applicable to human malignancies, the in vitro labeling approach has 
the caveat that clonal cell tracing cannot be induced after secondary tumor 
architectures have formed, and thus precludes access to clonal fate data of 
individual tumor cells. By combining the advantages of inducible clonal cell 
tracing and lentiviral delivery, we overcome these restrictions, and for the first 
time demonstrate a constant drift towards oligoclonality within colon cancer 
that appears to be based on clonal competition and axial outgrowth.  
Xenograft growth of  human  colon  cancer  cell lines seems to be the 
appropriate model as the architecture  and  tumor  cell  heterogeneity  of 
primary human colon cancers are properly reflected. By contrast, for studies 
addressing metastasis formation orthotopic tumor implantations would be the 
adequate model. However, in our study we examined clonal outgrowth of 
xenografts over relatively long periods of time (31 days) so that tumors reach 
diameters of up to 1.5 cm, which would be in conflict with orthotopic tumor 
implantation.   
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However, although we simulate these dynamics in our computer model by 
neutral stochastic competition of tumor cells at the leading tumor edge, the 
biological basis for clonal competition yet remains to be determined. Also, due 
to a limited number of different fluorescent colors, some aspects including the 
significance of neighboring clones with identical colors or clone fragmentation 
during outgrowth may be missed by our labelling strategy and require further 
study.  
Importantly, in our model this clonal competition does not depend on 
mutational evolution. Although additionally acquired mutations in individual 
tumor cell subclones may provide fitness advantage, genetic changes that 
substantially alter the clonal composition of a final tumor are assumed to be 
rare events in rapidly expanding cell populations (Korolev et al., 2010; 
McFarland et al., 2013). An inferred “Big Bang” model of colon cancer 
evolution therefore suggested that clonal dynamics in established tumors are 
mainly devoid of substantial mutational evolution (Sottoriva et al., 2015). In 
line with this idea, we found no differences in driver mutation profiles of 
individual tumor cell subclones. Therefore, we suggest that clonal competition 
in colon cancer is mainly determined by tumor cell positon, and may 
continuously occur throughout the lifespan of a tumor.  
Nevertheless, it remains to be determined to what extent other heritable traits 
may have an impact on clonal architecture and growth dynamics, since others 
reported epigenetic differences among subclones of colonic adenomas and 
colon cancers (Humphries et al., 2013; Siegmund et al., 2009). However, in 
contrast to unperturbed tumor growth, mutational evolution certainly plays an 
important role in acquired resistance to targeted therapy (Diaz Jr et al., 2012). 
Previous data suggested that treatment protocols stabilizing tumor growth 
rather than attempting to eradicate the tumor may prolong cancer survival 
(Gatenby et al., 2009). Our data suggesting continuous clonal competition 
may explain such findings. If treatment-resistant tumor subclones have to 
compete for space and resources with treatment-sensitive subclones that 
prevail under gentle targeted therapy, loss of resistant clones into tumor 
necrosis may occur by chance. In contrast, harsher targeted therapy may 
eliminate sensitive tumor cell clones and strongly favor a quick outgrowth of 
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resistant clones with earlier treatment failure. This hypothesis however, will 
require further experimental proof, and may then inform the design of future 
targeted therapeutic approaches for colon cancer patients.  
Discussion 
 
76 
 
6.2. PBX3 is part of an EMT regulatory network in colorectal cancer 
and indicates poor outcome 	
The ability of epithelial cancer cells to loose cellular junctions and polarity with 
subsequent infiltration of tumor surrounding stromal tissue is a main aspect of 
EMT and hallmark of cancer progression (Hanahan and Weinberg, 2011). 
Here we identify strong overexpression of PBX3 in tumor cells with high WNT 
activity undergoing EMT at the leading tumor edge of colorectal cancers. We 
demonstrate that PBX3 expression is induced in this tumor cell subset by 
WNT and the EMT regulating transcription factors SNAIL and ZEB1, while this 
induction – at least partially – occurs indirectly through a decreased 
repression of PBX3 mRNA by miR-200. These findings are in agreement with 
recent data that demonstrated targetability of PBX3 by different microRNAs 
(Han et al., 2015), and therefore place its expression in colon cancer 
downstream of a WNT and EMT regulatory network (Thiery et al., 2009). 
Furthermore, we demonstrate that PBX3 expression is required for a full EMT 
phenotype in colon cancer cells, since its depletion partially blocked EMT 
induction by ZEB1 and SNAIL, and increased the expression of E-cadherin, 
indicating a shift towards more epithelial differentiation. In line with this finding 
PBX3 has recently been shown to induce EMT in gastric cancer cells (Han et 
al., 2014; Li et al., 2017), indicating that it may generally be involved in EMT 
regulation in gastrointestinal cancers. Because PBX3 also has been shown to 
increase migration and invasion of colon cancer cells (Han et al., 2014) both 
of which are phenotypic characteristics of tumor cells undergoing EMT, this 
further supports the notion that PBX3 directly contributes to the infiltrative 
phenotype of colon cancer cells at the leading tumor edge. However, the 
exact mechanism by which PBX3 influences EMT in colon cancer still remains 
to be determined, keeping in mind that PBX3 may function as cofactor for 
homeobox proteins (Li et al., 2013).  
In primary colon cancer tissues, we found that PBX3 can easily be visualized 
in situ by immunostaining. Importantly, labelling in these tumors was restricted 
to cancer cells while tumor surrounding stromal cells were PBX3 negative. 
Given that markers which robustly indicate EMT in colon cancer are scarce, 
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and detection of ZEB1, SNAIL and Vimentin can be difficult and confounded 
by labelling of stromal cells (Francí et al., 2009; Spaderna et al., 2006; 
Toiyama et al., 2013), we propose that PBX3 may be a useful marker to 
highlight and further study colon cancer cells undergoing EMT in situ. 
Furthermore, we demonstrate that PBX3 mRNA levels strongly correlated with 
EMT in a large gene expression data set derived from 1,032 colon cancer 
samples. Considering the restriction of PBX3 expression to cancer cells, we 
therefore propose that on the gene expression level PBX3 may indicate the 
overall degree of EMT in colon cancer specimens with little confounding by 
the amount of stromal tissue within each sample. Of note however, PBX3 
expression was not completely restricted to infiltrative tumor cells at the 
leading tumor edge but also extended to glandular differentiated colon cancer 
cells, especially in cases with high levels of PBX3 expression. Because 
similar observations also were made for ZEB1 and SNAIL (Francí et al., 2009; 
Spaderna et al., 2006), it remains to be determined to what extent infiltrative 
tumor cell morphology and EMT related factors indicate identical or only 
partially overlapping colon cancer cell subpopulations. 
Our findings in case collections with clinical follow-up data demonstrate that 
PBX3 expression is strongly linked to poor outcome in patients with colorectal 
cancer. High PBX3 expression was significantly associated with poor cancer 
specific survival and strongly correlated with an increased risk for cancer 
progression in a collection of 244 stage II colorectal cancers, while this was 
independent of other core clinical variables. Stage II colorectal cancer is 
characterized by local disease with full-thickness involvement of the bowel 
wall but absence of lymphatic or distant metastasis (Edge and Compton, 
2010). Accordingly, most of these patients can be cured by surgical resection 
alone. However, disease progression after surgery still is observed in 25-30% 
of these cases and patients may eventually die from their disease (Dotan and 
Cohen, 2011). We therefore suggest that assessing PBX3 expression may 
identify potentially aggressive cases of stage II colorectal cancer that may 
benefit from adjuvant chemotherapy despite low clinical stage (Gunderson et 
al., 2010). Integrating PBX3 expression analysis into routine pathology 
workup of colorectal cancer specimens thus may guide the decision for 
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therapeutic management in addition to staging. However, PBX3 expression 
also strongly correlated with metastasis in our case control collection and thus 
also indicated disease progression in late stage disease. Moreover, we found 
that on the mRNA level PBX3 expression was highly significantly associated 
with poor outcome in a combined dataset with clinical information on 923 
colon cancers including all stages. This not only further confirmed our findings 
but also validated results from a previous study that suggested an association 
of PBX3 mRNA expression and poor patient survival in a smaller case 
collection (Han et al., 2014). Taken together, we here establish PBX3 as a 
robust marker for outcome stratification in patients with colorectal cancer. Due 
to its association with EMT, which regulates invasion and metastasis as a 
basis for cancer progression, we suggest that the independent prognostic 
power of PBX3 may be due to gauging EMT which is not sufficiently reflected 
by other clinical and pathological variables. 
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7. Summary 
 
Colon cancers are composed of phenotypically heterogeneous tumor cell 
subpopulations with variable expression of putative stem cell and 
differentiation antigens. While in normal colonic mucosa clonal repopulation 
occurs among differentiation gradients from crypt base towards crypt apex, 
the clonal architecture of colon cancer and the relevance of tumor cell 
subpopulations for clonal outgrowth are poorly understood.  
In the first study of this thesis, we used a multicolor lineage tracing approach 
in colon cancer xenografts that reflect primary colon cancer architecture. With 
this method, we could demonstrate that clonal outgrowth is mainly driven by 
tumor cells located at the leading tumor edge with clonal axis formation 
towards the tumor center. Our findings suggest that in colon cancer tumor cell 
position may be more important for clonal outgrowth than tumor cell 
phenotype. 
In a second study we analyzed colon cancer cells with high WNT signaling 
activity. This characteristic overactivation in colorectal cancers is caused by 
pathway activating mutations and drives tumor progression and metastasis. 
Here, we could identify pre-leukemia transcription factor 3 (PBX3) as a gene 
regulated in part by WNT signaling in colon cancers and assess its prognostic 
value. In a colon cancer case collection, PBX3 expression correlated with 
nuclear β-catenin and high PBX3 levels were associated with decreased 
patient survival and an increased risk for tumor relapse and metastasis. 
Additionally, an independent case control study confirmed the association of 
high PBX3 expression and colon cancer metastasis to the liver. Further 
studies provide evidence that PBX3 is also regulated by EMT. Knockdown 
and overexpression studies modifying the EMT transcriptions factors SNAIL 
and ZEB1 as well as PBX3 demonstrated that PBX3 is part of an EMT-
regulatory network in colorectal cancer.  
Taken together the results of these two studies may have implications for the 
cancer stem cell hypothesis, reveal new aspects of tumor cell heterogeneity in 
colorectal cancer, and could furthermore give insights for the design of new 
therapeutic strategies. 
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8. Zusammenfassung 
 
Dickdarmkarzinome bestehen aus phänotypisch heterogenen 
Subpopulationen von Tumorzellen, mit unterschiedlicher Expression putativer 
Stammzell- und Differenzierungsantigene. Während in normaler 
Dickdarmschleimhaut die klonale Besiedelung entlang 
Differenzierungsgradienten von der Basis der Krypte zur Spitze hin erfolgt, ist 
die klonale Architektur bei Dickdarmkarzinomen und die Bedeutung von 
Tumorzellsubpopulationen in Bezug auf den klonalen Auswuchs wenig 
bekannt.  
In der ersten Studie untersuchten wir Dickdarmkarzinom-Xenotransplantate, 
die die primäre Architektur des Kolonkarzinoms widerspiegeln, mithilfe eines 
multifarben „lineage tracing“ Ansatzes. Anhand dieser Methode konnten wir 
zeigen, dass Tumorzellen am Tumorrand hauptsächlich für das klonale 
Wachstum im Tumor verantwortlich sind und sich dieses entlang einer Achse 
zum Tumorzentrum hin erstreckt. Diese Ergebnisse zeigen, dass im 
Dickdarmkarzinom für das klonale Wachstum die Position der Tumorzellen 
offenbar wichtiger ist als deren Phänotyp. 
In einer zweiten Studie untersuchten wir Tumorzellen mit hoher WNT 
Signalwegaktivität. Diese für Kolonkarzinome charakteristische 
Überaktivierung entsteht durch den Signalweg aktivierende Mutationen und 
trägt zur Tumorprogression und Metastasierung bei. Hierbei entdeckten wir, 
dass Prä-Leukämie Transkriptionsfaktor 3 (PBX3) im Kolonkarzinom zum Teil 
durch den WNT Signalweg reguliert wird. In einer Fallsammlung von 
Dickdarmkarzinomen überlappte die PBX3 Expression mit nukleärem β-
catenin und hohe Expressionslevel von PBX3 konnten mit einem geringeren 
Patientenüberleben sowie mit erhöhtem Risiko eines Tumorrezidivs und 
Metastasenbildung assoziiert werden. Des Weiteren konnte eine unabhängige  
Fallstudie den Zusammenhang zwischen hoher PBX3 Expression und 
Metastasen des Dickdarmkarzinoms bestätigen. Weitere Experimente 
lieferten den Beweis, dass PBX3 zudem durch EMT reguliert wird. RNA 
Interferenz und Überexpressionsstudien bei denen die EMT 
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Transkriptionsfaktoren SNAIL und ZEB1 sowie PBX3 modifiziert wurden, 
zeigten, dass PBX3 Teil eines EMT-regulatorischen Netzwerks beim 
Dickdarmkarzinom ist. 
Zusammenfassend haben die Ergebnisse dieser Studien Auswirkungen auf 
die Stammzellhypothese und zeigen neue Aspekte der 
Tumorzellheterogenität beim Dickdarmkrebs auf. Darüberhinaus können sie 
für die zukünftige Entwicklung neuer therapeutischer Strategien hilfreiche 
Einblicke geben.            
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9. Abbreviations 
 
AML acute myeloid leukemia 
APC adenomatous polyposis coli 
APS ammonium peroxodisulfate 
BFP blue fluorescence protein 
BlastR blasticidin resistance 
Bmi1 B lymphoma Mo-MLV insertion region 1 homolog 
bp basepairs 
BrdU Bromodeoxyuridine 
BSA bovine serum albumin 
CBC crypt based columnar cell 
CDK cyclin-dependent kinase 
cDNA complementary DNA 
CE clonal evolution 
CIN chromosomal instability 
CK1 casein kinase 1 
CRC colorectal cancer 
CSC cancer stem cell 
CFP cyan fluorescent protein 
DAPI 2-(4-amidinophenyl)-6-indolecarbamidine dihydrochloride 
DMEM Dulbecco`s modified Eagles medium 
DMSO dimethyl-sulfoxide 
DNA deoxyribonucleic acid 
dnTCF4 dominant negative TCF4 
dNTP deoxynucleotides triphosphate 
DOX doxycycline 
Dvl dishevelled 
E.coli Escherichia coli 
EGFR epidermal growth factor receptor 
EMT epithelial-mesenchymal transition 
FBS fetal bovine serum 
FoxC2 Forkhead box protein C2 
GSEA Gene Set Enrichment Analyses 
GSK3 glycogen synthase kinase 3 
HCC hepatocellular carcinoma 
Hopx HOP homeobox 
HRP horseradish peroxidase 
IF immunofluorescence 
IHC immunohistochemistry 
int-1 integrated 1 
KLF8 krueppel-like factor 8 
LB lysogeny both 
   Abbreviations 
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LEF1 lymphoid enhancer-binding factor 1 
let-7 lethal-7 
Lgr5 leucine rich repeat containing G protein coupled receptor 5 
LRP 5/6 lipoprotein receptor related protein 5/6 
LTR long terminal repeat 
MAPK mitogen-activated protein kinase 
MET mesenchymal-epithelial transition 
miR microRNA 
MMR mismatch repair 
mRNA messenger RNA 
MSI microsatellite instability 
mut mutated 
NIH National Institutes of Health 
OFP orange fluorescent protein 
ORF open reading frame 
PBX pre-B-cell leukemia homeobox 
PBS phosphate buffered saline 
(q)PCR (quantitative) polymerase chain reaction 
PI3K phosphoinositide-3-kinase 
pri-miR primary microRNA transcript 
PuroR puromycin resistance 
RFP red fluorescent protein 
RNA ribonucleic acid 
RT room temperature 
RUNX3 runt-related transcription factor 3 
SD standard deviation 
SDS sodium dodecyl sulfate 
TAM tamoxifen 
TCF T cell transcription factor 
Temed tetramethylethylenediamine 
Tert telomerase reverse transcriptase 
Tet tetracycline 
TF transcription factor 
TGFB1 transforming growth factor –β 
TIC tumor-initiating cell 
TMA tissue microarray 
TRE tetracycline response element 
TRS target Retrieval Solution 
TSP1 thrombospondin 1 
TSS transcription start site 
RFP red fluorescent protein 
rtTa reverse tetracycline-controlled transactivator 
UTR untranslated region 
VSV vesicular stomatitis virus (tag) 
   Abbreviations 
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WB western blot 
WT wild-type 
XFP fluorescent protein 
YFP yellow fluorescent protein 
ZEB zinc finger E-box-binding homeobox protein 
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